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  Summary 
  I 
Summary 
In the present thesis, the development of stimuli-responsive amphiphilic peptides for 
biomedical applications is described. The thesis is structured into four projects: (i) 
composite peptide–gold nanoparticle superstructures, (ii) reduction-responsive codelivery 
of antisense oligonucleotides and drugs, (iii) peptidic gene transfection, and (iv) reduction-
responsive highly sensitive MRI contrast agents (Figure I). 
	
Figure I. Projects described in the present thesis. Adapted from Gunkel-Grabole et al.1 and deBruyn et 
al.2 
Severin J. Sigg 
II 
Chapter one comprises a general introduction to self-assembled systems in nature and their 
inspiration and influence on artificially designed functional nanomaterials. Further, concepts 
and recent achievements of nanoarchitectures for biomedical applications are introduced 
with focus on peptides as molecular building blocks, including assemblies based on 
gramicidin A derived amphiphilic peptides. It also contains a brief background of the 
underlying theory of magnetic resonance imaging (MRI) contrast agents, an overview of 
FDA-approved contrast agents, and recent advances regarding responsive MRI contrast 
agents. Furthermore, solid phase peptide synthesis is shortly introduced, and the aim of the 
thesis is presented. 
Chapter two reports the development and investigation of amphiphilic peptides capable of 
forming composite peptide–gold superstructures (Figure I–i). Amphiphilic peptides based 
on a hydrophobic sequence derived from gramicidin A in conjunction with acetylated 
polylysine were modified with cysteines offering binding sites for covalent attachment to 
gold. Peptide-coated gold nanoparticles were able to self-assemble into ordered gold 
nanoparticle superstructures. 
Chapter three addresses the elaboration of a reduction-responsive codelivery carrier for 
antisense oligonucleotides and small molecule drugs (Figure I–ii). Amphiphilic peptides 
were designed to bear nucleic acid binding units and hydrophobic sequences able to self-
assemble into peptide nanoparticles incorporating desired payloads of different 
physicochemical characteristics. Introduction of a reduction-cleavable linker to the peptide 
sequence allowed triggered release of the cargoes at elevated levels of reduction potential. 
Chapter four reveals peptidic gene transfection studies based on nanocarriers self-assembled 
from amphiphilic peptides comprising polylysine and polyhistidine sequences (Figure I–iii). 
The constructs were optimized for entrapment of GFP-encoding plasmid DNA, which 
subsequently served to assess the transfection performance via fluorescence levels. 
Transfection efficacies and effects on cells were investigated at various conditions. 
Chapter five includes the development of highly sensitive magnetic resonance imaging 
contrast agents with contrast enhancement in reductive milieu (Figure I–iv). Gadolinium 
was complexed with heparin-poly(dimethylsiloxane) block copolymers and coassembled 
with a reduction sensitive amphiphilic peptide to form spherical nanoparticles. Magnetic 
resonance imaging contrast enhancement was examined simulating elevated levels of 
reduction potential, as found in tumor tissue, and compared to nontreated coassembled 
nanoparticles and a commercially available contrast agent. 
Chapter six concludes the findings and achievements of the performed research. The results 
are discussed and promising further research directions are suggested and highlighted. 
Further, it comprises general statements regarding rational design of peptide sequences for 
controlled self-assembly and underlines their large potential towards biomedical applications. 
  Summary 
  III 
Chapter seven summarizes materials and methods. Individual experimental setups for all 
presented research projects are described in detail, including source and grade of chemicals, 
origin of materials, devices, and instruments, as well as measurement parameter and 
formulae. 
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Chapter 1 
1 Introduction 
The first chapter provides a general introduction to the fields of self-assembly, molecular 
design, responsive nanomaterials, and their applications in biomedicine, such as for drug 
and/or gene delivery and as magnetic resonance imaging contrast agents. A special focus 
is laid on nanostructures built from pure peptides including their advantages compared 
to other materials. The chapter further encloses a brief introduction to solid phase 
synthesis as well as a subchapter comprising the scope of the present thesis. 
 
 
 
 
Parts are adapted from Biomaterials Science: 
Gunkel-Grabole, G.; Sigg, S.; Lomora, M.; Lörcher, S.; Palivan, C. G.; Meier, W. P. Polymeric 3D 
nano-architectures for transport and delivery of therapeutically relevant biomacromolecules. 
Biomater. Sci. 2015, 3, (1), 25-40, with permission from the Royal Society of Chemistry. 
Parts are adapted from Chimia: 
Sigg, S. J.; Schuster, T. B.; Meier, W. P. Self-assembled Structures from Amphiphilic Peptides. Chimia 
2013, 67, (12), 881-884. © 2013, Swiss Chemical Society. 
	
Figure 1. Various self-assembly architectures. Introduced and described in more detail in the 
following chapter. 
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1.1 Self-Assembly – The Basis of Life 
Why is it necessary to understand self-assembly to understand life? Autonomous 
organization of components to form structures without external intervention is known as 
self-assembly. Self-assembly encloses all length scales – from molecular dimensions to 
planetary systems, galaxies and beyond. It is expressed by the order of systems and is 
represented by numerous essential mechanisms in nature. Biologic processes are mainly 
based on highly organized structures. Of particular importance regarding life-essential self-
assemblies is the double stranded DNA – the “construction plan“ of biological systems. Its 
nucleotide building blocks can bear four different nucleobases and are coupled in unique 
sequences encoding for a multitude of functional and regulatory biomolecules. Specific 
nucleic acids initiate the production of enzymes and proteins, which then form secondary, 
tertiary and quaternary structures defining their functionality in the living system. Moreover, 
self-assembly is the underlying physicochemical mechanism for the formation of 
phospholipid bilayers, essential for creation of confined space in living organisms, for 
instance in cell walls and compartmentalization inside cells.3 
1.2 Synthetic Self-Assemblies 
In the past decades, numerous material scientists transferred the evolutionary success of 
nature about self-organization towards the creation of hierarchical structures with tailored 
properties. Microstructures were initially built by reduction of size, so called “top-down” 
fabrication, usually generated by lithographic techniques. As top-down approaches reached 
their limits at about one micrometer, it became increasingly clear that fundamental 
understanding of self-assembly in biological structures is necessary to close the gap between 
the nanometer size molecules produced by chemical synthesis and nanoparticles formed by 
top-down fabrication. The “bottom-up” approach was developed. It deals with the design of 
molecular structures able to interact due to mutual recognition properties based on 
noncovalent bonding. Contributing molecular forces are mainly electrostatic and 
hydrophobic interactions as well as π–π-stacking. Assembling instructions for larger 
structures are encoded within structural motifs and affinities of the molecular building 
blocks. DNA origami, for instance, nicely represents the bottom-up approach of self-
assembling nanostructures to build various three-dimensional objects (Figure 2). 
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Figure 2. Engineering self-assembling three-dimensional nanoobjects from DNA using DNA origami 
technique. From Han et al., Science (2011).4 Reprinted with permission from AAAS. 
Appropriate molecular design can yield a variety of supramolecular assembly architectures 
such as micelles, fibers, tubes, multicompartment micelles, vesicles, planar membranes, and 
lamellar structures (Figure 3). Micelles are spherical objects formed by amphiphilic 
molecules in aqueous solution. This process is driven by an enhanced level of free energy due 
to the exposure of hydrophobic moieties to water. To overcome this, the molecules begin to 
orient themselves, hiding hydrophobic parts in a core surrounded by hydrophilic corona. In 
vesicles, nanocompartmentalization occurs by separation of the inner medium from its 
exterior by lipid (liposomes),5,6 polymer (polymersomes),7-10 or peptide membranes 
(peptosomes).11-13 The cavity is appropriate for sheltering fragile biomolecules such as 
proteins and enzymes, or to lock up soluble toxic payloads.14 Moreover, when permealizing 
the vesicle membranes they have been shown to function as nanoreactors.15-17 Many of these 
approaches are nature inspired and adapted from lipid membranes. Lipid membranes are 
omnipresent in nature and serve as a role model for the design of synthetic analogues with 
improved stability and functionality.18 
	
Figure 3. Common architectures of self-assembling amphiphiles. Hydrophilic-to-hydrophobic ratio, 
chemical and physical properties of the blocks, and assembly conditions among other parameter 
influence the self-assembly process. 
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1.2.1 Peptides 
Peptides represent a special class of self-assembling molecules due to their ubiquitous 
appearance as proteins or enzymes, where they exhibit extraordinary folding skills leading to 
defined tertiary structures. In biomedical applications, such as drug delivery, artificially 
designed peptides are very promising candidates. This is due to their inherent 
biocompatibility and biodegradability but also because of the ease of synthesis, 
functionalization, and their defined molecular structure. The building units are amino acids. 
There are 20 canonical amino acids used in natural biological systems. With the exception of 
glycine, all are chiral and hence can have two configurations, although generally only the L-
configuration is of biological importance. Depending on their sequence, peptides form 
ordered secondary structures such as α-helices or β-sheets, stabilized by noncovalent 
interactions such as hydrogen-bonding, π–π-stacking, and ionic and hydrophobic 
interactions (Figure 4). Due to the large variety of building units, a nearly endless number of 
unique peptides can be designed, each with its three-dimensional conformation and 
properties. 
In past decades, many peptide-based materials have been investigated, the main groups being 
peptide amphiphiles (PAs)19,20 and amphiphilic peptides (APs). The latter consist solely of 
amino acids, in contrast to peptide amphiphiles, which comprises other groups such as alkyl 
chains, phospholipids and polymers.21,22 There are several recently published reviews 
covering the field of PAs.19,21 
	
Figure 4. Common secondary structures of peptides stabilized by hydrogen bonding (marked in 
yellow). The α-helix (left) is righthand-coiled and stabilized by hydrogen bonding from N–H to the 
C=O four residues earlier. β-sheets (right) are laterally connected by hydrogen bonds. 
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The sequence of amphiphilic peptides is organized into two regions: the hydrophobic and 
the hydrophilic. The latter is predominantly occupied by charged and polar amino acids; 
these are: arginine (R),23,24 histidine (H),24,25 lysine (K),26-32 aspartic acid (D),33,34 glutamic 
acid (E),11,28 serine (S), threonine (T),35 asparagine (N), glutamine (Q),36 and cysteine 
(C).30 The design of the former region is based on amino acids with neutral and nonpolar 
side-chains such as glycine (G),33 alanine (A),32,37 valine (V),34,38 leucine (L),26,34 isoleucine 
(I),39 methionine (M), phenylalanine (F),40,41 tyrosine (Y), and tryptophan (W).24,27-31,41 
Depending on the hydrophobic to hydrophilic ratio and the sequence, various self-assembled 
structures can be constructed – as indicated in the associated references for the above amino 
acids – although the hydrophobicity is moderated by the polar character of the peptide 
backbone. 
Nanomaterials created from those amphiphiles allow additional tuning towards the required 
functions and properties by design and functionalization of sidechains and endgroups. Every 
amino acid has its benefits; cysteine, for instance, can be used as a connection point for 
labeling or to covalently attach gold. Mastrobattista’s group presented studies of conical 
shaped amphiphilic peptides self-assembling into vesicles with a hydrodynamic radius of 
about 60 nm.11 Their sequences consist of A, L, V, and W for the hydrophobic moity, and 
various lengths of glutamic acid as the hydrophilic region. Gazit et al. reported short aromatic 
Fmoc-peptides that form spheres, tubes, and fibrils.42 Zhang’s group published work about 
surfactant-like peptides, which can self-assemble into vesicles and fibers.33 
In our group, various different de novo designed peptides have been created and investigated 
(Figure 5). All peptides were designed based on a hydrophobic sequence derived from 
gramicidin A, an antibiotic that inserts into lipid membranes. The sequence and secondary 
structure of gramicidin was investigated by Sarges et al.43 Hydrophobicity is generated by its 
helical secondary structure, hiding the peptide’s backbone from its surrounding milieu. This 
knowledge can be adapted to a variety of amphiphilic peptides. Based on the native sequence, 
two hydrophobic sequences were developed, namely gA (-V-G-A-DL-A-DV-V-DV-[W-DL]3-
W-NH2) and a truncated version gT, comprising only the L-tryptophan-D-leucine repeating 
unit (-[W-DL]3-W-NH2). Both, the gA and gT hydrophobic segments have a C-terminal 
amide group. Circular dichroism and infrared spectroscopic investigations revealed a 
secondary structure that included a β-turn motif and hydrogen bonds for the gT 
hydrophobic sequence.31,44 The crucial influence of secondary structure on their self-
assemblies was shown by replacing D-leucines with L-leucines, whereby the gT hydrophobic 
sequence changed its secondary structure such that amphiphilic nature was no longer 
present, leading to amorphous assemblies.31 Charged or polar amino acids such as lysine, 
acetylated lysine (X), and/or glutamic acid served as the hydrophilic sequences. 
Oligopeptides comprising trilysine hydrophilic regions, form micelles with hydrodynamic 
radii of about 10 nm. They similarly exhibit a surfactant-like behavior, e.g. the critical micelle 
concentration (CMC) is 0.23 mmol L-1.29 Decreasing the number of charges by acetylating 
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the lysines in the hydrophobic sequence lowers the overall hydrophilicity owing to the 
formation of spherical objects in the sub-micrometer range. The formation process proceeds 
over micelles, which then aggregate with decreasing ethanol content to form peptide 
nanoparticles. 
	
Figure 5. Overview of self-assembled structures using amphiphilic peptides ranging from micelles, 
fibers, vesicles and lamellar structures to spherical nanoparticles. Reproduced from Sigg et al.45 
To understand the impact of changes in the primary sequence on self-assembly a library of 
peptides were produced systematically changing properties. Beginning with K8gA, the 
lysines were successively acetylated to AcX8gA, comprising no charges and therefore no 
electrostatic repulsion. Interestingly, between K2X6gA and K3X5gA the secondary structure 
of the hydrophilic region changed dramatically from β-sheets to α-helices, accompanied by 
different properties. K2X6gA was self-assembling into fibers with a length ranging from 30 to 
800 nm while K3X5gA formed micelles and worm-like micelles.27 These results concur with 
recently published studies by Lee and coworkers.46 According to those studies, peptides with 
β-sheet secondary structure preferentially form fibers, due to the stacking of the radially 
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ordered unimers. The micellar core also provides space for hydrophobic drug encapsulation 
and can thus be used as drug delivery system.47-49  
To create polymersomes or polymeric membranes block-copolymers are regularly used, 
including poly(2-methyloxazoline)-b-poly(dimethylsiloxane)-b-poly(2-methyloxazoline) 
(PMOXA-b-PDMS-b-PMOXA),17 polyethyleneglycol-b-poly(γ-methyl-ε-caprolactone) 
(PEG-b-PMCL),50 poly(ethylene glycol)-b-poly(γ-methyl-ε-caprolactone)-b-poly[(2-di-
methylamino)ethyl methacrylate] (PEG-b-PMCL-b-PDMAEMA),51 and poly(butadiene)-
b-poly(ethylene glycol) (PB-b-PEG).52 Similarly, peptidic analogues can be constructed. For 
tuning amphiphilic peptides based on gA or gT hydrophobic sequences to form peptosomes, 
hydrophobic interactions and geometrical parameters have to be adjusted and optimized. 
Masking the C-terminal amide of fully acetylated AcX8gA by esterification (AcX8gA-OEt) 
led to the formation of vesicles. Improving perpendicular interaction with respect to a 
membrane facilitated membrane formation. Additionally, an increase of lateral interactions 
similarly promoted the formation of membranes. Replacing the hydrophilic sequence with 
hexaglutamic acid allowed intermolecular interaction of the carboxylic group, which 
stabilized the formation of micelles and vesicles.53,54 From a conceptual point of view, peptide 
membranes are fascinating as analogues to lipid and polymer membranes. However, the low 
number of publication may illustrate the challenges associated, in particular when using 
short, amphiphilic oligopeptides. Nevertheless, encapsulation properties of such amino acid 
based materials may allow their use as a drug and gene delivery vehicles.55 In this respect, 
proven polymersomes concepts, such as targeting, may also lead to a fast development of 
advanced peptosomes.56,57 The variety within the amino acid alphabet opens a vast 
playground for controlling self-assembly. By introducing desired interactions such as 
hydrogen bonds and charge compensation, highly ordered organizations can be created.58,59 
Shorter variants of the acetylated peptides (AcX3gT) yielded spherical nanoparticles.30,31 
Characterization of the nanoparticles exhibited a particle scattering factor and a ρ-parameter 
(Rg/Rh) that confirm the beads to be solid spheres.29,30 Their density was determined to be 
about 1.4 g cm-3.30,31 Their size was dependent on the initial peptide concentration, ranging 
from a diameter of 260 to 800 nm.30 Underlying self-assembly process and inner structure of 
the peptide nanoparticles are based on micelles, which then aggregate in a controlled manner 
to form highly spherical nanoparticles (Figure 6).  
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Figure 6. Hierarchical self-assembly of AcX3gT into multicompartment micelles (a). SEM 
micrograph of an AcX3gTC peptide nanoparticle, revealing insight into the inner structure (b). 
Reproduced from Sigg et al.45 
Based on the available data they have been hypothesized to be multicompartment micelles 
(MCM).30 Multicompartment micelles exhibit outstanding properties and are therefore 
attractive for a broad variety of applications in nanotechnology.60-62 Similarly, peptidic 
analogues provide new opportunities concerning drug delivery applications and functional 
materials. 
1.3 Drug/Gene Delivery 
Nanotechnology provides a vast array of opportunities and tremendous promise for the 
rational design of multifunctional drug delivery systems. Nanocarriers are designed for 
delivery of therapeutics: protecting them from being metabolized,63,64 enhancing 
bioavailability,65,66 lowering off-target effects, and decreasing the necessary drug dose by 
increasing accumulation at the diseased site. Ideally, drug delivery systems have sizes of 100 
to 200 nm67,68 to avoid excessive clearance by phagocytic cells in liver and spleen,69,70 and 
renal filtration.71 Further improvement of efficacy can be achieved by utilizing physiological 
microenvironments at pathological sites such as pH,72-75 temperature,76 and redox 
potential77,78 as release triggers.  
 Chapter 1 
  9 
1.3.1 Nanocarrier Architecture 
To develop nanocarriers capable of delivering drugs and/or genes with high efficiency the 
carrier architecture is a crucial factor. Although there is no gold standard nanocarrier design, 
numerous publications in the field allow drawing trends and conclusions. Importantly, the 
chemical structure, size and properties of the desired payload, as well as the target location in 
the body play an important role in choosing the right nanocarrier design. They can be 
divided into four main groups independently of their chemical nature: dendrimers, micelles, 
vesicles, and nanoparticles (Figure 7). Each design bears advantageous individual features 
matching the needs of specific applications. Building blocks can be made of diverse chemical 
compositions comprising lipids, polymers, peptides, and inorganic materials. Important 
properties arising from the underlying molecular design are size, functional groups, nature of 
compartmentalization, surface properties, stability, compatibility, and degradability among 
others.  
Dendrimers are normally synthesized to 4th or 5th generation for biomedical applications. The 
comparably small constructs are monodisperse, therefore well defined single molecules, 
which exhibit high stability and the ability be chemically modified with payload binding or 
recognition moieties. On the other hand, based on the small sizes, in vivo application usually 
lacks efficiency due to rapid clearance via renal pathways. Furthermore, dendrimers 
developed for delivering nucleic acids revealed high cytotoxicity because of the high charge 
density disrupting cell membranes.79,80 Similarly, micelles exhibit rather small sizes for in vivo 
applications dependent on the length of the single molecules. However, the assembly 
architecture offers a hydrophobic environment in the core, allowing entrapment of 
hydrophobic payload.47,48,81 In contrast, vesicular constructs bear a hydrophilic inner cage 
with larger spatial dimensions compared to micelles. The larger volume of the inner cavity 
enables the delivery of higher doses; furthermore, renal clearance is avoided. However, 
reaching diameters above 200 nm considerably large amounts of the applied constructs are 
being removed from the blood stream by phagocytosis. For drug delivery purposes the 
stability of vesicles is a major issue. Originally built from lipids inspired by nature, vesicles 
were increasingly designed from polymers and peptides revealing higher stabilities.10,82 
Spherical nanoparticles enclose all remaining nanoscale assembly architectures, which are 
not specifically defined. The assembled nanostructures are usually described via size, shape 
and abilities to entrap and release drugs and/or genes, rather than via specific bottom up 
molecular self-assembly.83-87 
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Figure 7. Different architectures of drug delivery devices (top row). Strategies to deliver drugs 
compared to the application of free drugs (bottom row). 
1.3.2 Stimuli-Responsiveness 
The efficiency of drug delivery systems is often limited by the control of the release of the 
payload. Nonspecific release follows the Fickian diffusion and is not sufficient for many 
applications. Furthermore, systemic biodistribution of the nanocarriers alters efficacy of the 
delivered drugs by nonspecific release. More efficient strategies include on-demand 
processes, which enable control over the drug release profile. On-demand drug delivery can 
be achieved by endogenous or extracorporeal stimuli. Former targets distinct physiologic 
microenvironments at pathological sites such as pH, redox potential, temperature, or 
concentration of certain enzymes, and reacts by releasing the payload. Latter involves 
extracorporeal physical stimuli including light, temperature, and ultrasound.88 
pH-responsive systems are designed to react to elevated proton concentrations. The pH of 
extracellular environments of solid tumors (6.5–7.2) is slightly lower compared to healthy 
tissue (~7.4).88 In order to obtain an efficient release of payload, the nanocarrier must be 
designed to give a sharp response to this small change in pH. For example, PEG-poly(amino 
ester) micelles were reported to release camptothecin upon a pH change to 6.4.89 Other 
acidic compartments develop during the endocytotic cell uptake pathway. The pH drops 
gradually from early endosomes (6.5) to late endosomes (~6.0) to lysosomes (4.5–5.0).90 
Complexes of styrene-maleimic acid copolymer and the anticancer drug cisplatin revealed 
much faster in vitro release at pH 5.5 compared to physiological pH (7.4).91 pH-responsive 
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release of small molecule drugs at acidic conditions was also reported for poly(β-amino 
ester)-capped mesoporous silica nanoparticles92 and core cross-linked polyphosphoester 
micelles.93 Another study describes hollow chitosan-silica nanospheres that reveal faster 
release profiles of bovine serum albumin, as a model enzyme, at pH 4.0 compared to 
physiological conditions.94 
Inflamed areas and tumors are often hyperthermic,76 thus differing in temperature compared 
to healthy regions in the body. In order to develop effective nanocarriers exploiting this small 
temperature differences a sharp change in properties with temperature is required. 
Nanocarrier designs involving poly(N-isopropyl acrylamide) demonstrated improved drug 
release at hyperthermic regions due to a lower critical solution temperature close to body 
temperature.95-100 Other architectures include thermo-responsive poly(amino acid)-based 
micelles,101 block copolymer coated magnetic iron oxide nanoparticles,102 and various 
liposome designs.103 
Redox sensitive drug delivery systems react to intracellular glutathione (GSH) 
concentrations that are three orders of magnitude higher (2–10 mM) compared to 
extracellular levels (2–10 µM). Reduction-triggered release is also promoted by higher 
reduction potential in tumor tissue compared to healthy tissue. The development of 
reduction sensitive drug delivery systems is focused, but not limited to disulfide linkages 
cleavable by GSH. Recent studies report disulfide cross-linked polymeric micelles designed 
to deliver the anticancer drugs doxorubicin,104 paclitaxel,105 methotrexate,106 and 
vincristine,107 as well as DNA108 with high efficiencies. Other examples include bioreducible 
systems based on heparin nanogels that release doxorubicin after addition of GSH109 and 
peptide amphiphile-capped mesoporous silica nanoparticles that release doxorubicin after 
addition of physiological concentrations (10 mM) of dithiothreitol (DTT).110 
Light-triggered drug delivery systems are responsive to illumination with light in the ultra 
violet (UV), visible, or near infrared (NIR) region.111 UV- and visible-light responsive drug 
delivery systems utilize cis–trans isomerization of azobenzene derivates,112-114 spiropyran–
merocyanine isomerization,115 and photodimerization–cleavage cycles of thymine,116 among 
others. However, UV and visible light induced drug release is limited by the low penetration 
depth due to strong scattering inside soft tissues, thus only applicable to eyes and skin. Drug 
delivery systems triggered by light in the NIR-region has the advantages of deeper tissue 
penetration and minimal harm to tissue. The thermoplasmonic properties of gold 
nanoparticles provide a promising platform for NIR-induced drug release. Examples include 
NIR-triggered release of a model drug117,118 or doxorubicin117 from mesoporous silica-coated 
gold nanorods, release of single stranded DNA (ssDNA) from gold-coated silica 
nanoparticles via dehybridization,119 and controlled release from polyelectrolyte coated gold 
nanorods.120 
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1.3.3 Nucleic Acid Delivery 
Besides small molecule drugs, nucleic acids, such as plasmid DNA (pDNA), short interfering 
RNA (siRNA), and therapeutic antisense oligonucleotides (AON) demand for 
multifunctional delivery systems. For delivery, nucleic acids are condensed to smaller sizes 
using polycations such as polyethylenimine (PEI), poly-L-lysine (PLL), spermidine, histones, 
and other cationic lipids, peptides or polymers. Enhancement of cell uptake can be achieved 
by recognition sequences or specific moieties interacting with cell membranes. These can be 
directly included in the sequence of peptides used for nanoparticle formation while for 
polymeric systems they need to be coupled post-synthesis. Naturally occurring cell-
penetrating peptides (CPPs) like RGD, polyarginine, MPG, MAP, KALA, pVEC, and Tat are 
often used in this respect (Table 1). Successful DNA delivery has been reported with 
modified pVEC,121 and KALA peptides modified with an additional RGD cell adhesion 
motif.122 Efficient transfection was obtained using peptide amphiphiles bearing both an RGD 
sequence and an octaarginine (R8) cell penetrating peptide.123 To improve the localization of 
nanocarriers, specific targeting to LHRH-receptors (usually overexpressed in breast cancer 
cells)124 was achieved with lysine- and histidine-rich peptides.25 pH-triggered release of DNA 
was facilitated by using nanoparticles of carboxymethyl poly-L-histidine (CM-PLH) and 
poly-β-amino ester. The CM-PLH coating significantly decreased the cytotoxicity and at the 
same time improved the specific localization at tumor sites due to the enhanced permeability 
and retention effect (EPR effect).125 Dendronized polypeptides, containing histidine, 
phenylalanine, and a backbone bearing disulfide bonds were able to release siRNA upon 
reduction.126 Moreover, KALA peptides decorated with RGD-moieties were used to 
condense DNA. These peptides were oligomerized to obtain di-, tri-, and tetramers via a 
disulfide linker during the formation process, which subsequently acted as reduction 
sensitive part of the nanoparticles.  
Table 1. Names and Sequences of Cell-Penetrating Peptides. Sequences are Noted According to 
the Mentioned References. Length of Sequences may Differ From Other Literature. 
code/name sequence reference 
RGD RGD 123 
MPG GALFLGFLGAAGSTMGAWSQPKKKRKV 127 
MAP KLALKLALKALKAALKLA 127 
KALA WEAKLAKALAKALAKHLAKALAKALKACEA 127 
pVEC LLIILRRRIRKQAHAHSK 121 
R8 RRRRRRRR 123 
R9 RRRRRRRRR 128 
Tat GRKKRRQRRRPPQ 127 
PTD4 YARAAARQARA 128 
Transportan GWTLNSAGYLLGKINLKALAALAKKIL 128 
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Besides, nucleic acid cargo can also be delivered and released from polymeric nanoparticles. 
Linear cationic click polymers containing disulfide bonds, secondary amine groups, and 
amide–triazole moieties were reported to deliver and release pDNA in a reductive 
environment, if the DNA had been condensed with PEI first.129 Moreover, efficient delivery 
of a nucleic acid payload to mesenchymal stem cells, which is of high interest in regenerative 
medicine, was recently reported.128,130 In this study, a pH-responsive diblock copolymer 
composed of PDMAEMA, poly(butyl methacrylate) (PBMA) and poly(propylacrylic acid) 
(PPAA) was used to form nanoparticles of siRNA and the copolymer. In addition, successful 
dual gene knockdown in ovarian tumors in vivo is described for short hairpin RNA (shRNA) 
condensed with PLL/PLGA nanoparticles.131 In addition to purely peptidic and purely 
polymeric systems, polymer-protein conjugates can also form nanoparticles and deliver 
pDNA, as shown for example using BSA-poly(dimethylamino) ethyl methacrylate (PDMA) 
based nanoparticles.132 
To date, a variety of nanoparticles have been developed and proved their functionality in 
vitro. However, only a few of them also showed applicability in vivo.124,125,129,131,133,134 Despite 
favorable effects on internalization, positively charged nanoparticles tend to agglomerate 
upon contact with serum proteins, leading to accumulation in thin capillaries and ultimately 
cause blockage of the blood stream. Further, a balance has to be kept between the several 
desirable requirements for drug delivery systems and the need to reduce the complexity of 
assembled nanoparticles. This is of particularly importance to avoid possible sources of error 
since the preparation process is statistical.  
Antisense oligonucleotides represent a special form of therapeutic nucleic acids. AON are 
typically short single-stranded oligonucleotides with about 20 bases and backbones that are 
usually chemical modified phosphothioate linkages between the nucleosides to obtain better 
stability.135 They inhibit target mRNA by Watson-Crick base pairing leading to down-
regulation of protein production. For the delivery of AON, two main strategies are followed: 
either synthetically conjugated to the carrier or noncovalently condensed.63 Covalent 
strategies were recently reviewed and describe the linkage of lipids, peptides, carbohydrates 
and small molecule moieties to the 5' or 3' positions of the AON.136 The bound moieties 
should not interfere with the binding to target RNA to obtain efficacious delivery systems. 
Noncovalent condensation is achieved via electrostatic interaction with the negatively 
charged backbone of the AON to positively charged carrier molecules. Noncovalent 
nanocarriers for AON delivery are usually better able to cross cell membranes and deliver the 
cargo than conjugated ones.137 Mipomersen is the first FDA-approved AON drug targeting 
the mRNA encoding for a protein involved in the production of the low-density lipoprotein 
cholesterol (LDL-C), also called bad cholesterol. Clinical studies showed 25% lower LDL-C 
levels in patients with homozygous familial hypercholesterolaemia.135 Further AON drugs are 
curstirsen, which targets an upregulated protein in prostate cancer, and fomivirsen, for the 
treatment of cytomegalovirus-induced retinitis for patients with AIDS.135 
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1.3.4 Combined Treatments 
Many studies about combined treatment with different therapeutics (drug–drug, drug–
nucleic acids) showed very promising synergistic effects. To exploit the full potential of 
combined treatments, multifunctional delivery systems must be capable of delivering various 
kinds of payloads simultaneously to the desired place. This can be a combination of small 
molecule drugs, which exhibit a synergistic characteristic when applied in combination. For 
instance, combined treatment with the anticancer drugs dihydroartemisinin and doxorubicin, 
revealed synergistically increased inhibition of cell proliferation.138 Synergistic effects were 
also observed for the treatment of prostate cancer with a combination of the flavonoid 
vicenin-2 and docetaxel.139 A further example is the use of small doses of curcumin and 
paclitaxel, which showed synergistic effects in the treatment of the highly chemo-resistant 
human brain tumor stem cells.140 Synergistic characteristics were also shown for 
combinations of micro RNA (miRNA) with small molecule anticancer drugs such as 
gemcitabine, doxorubicin, doxetaxel, epirubicin, and adriamycin141 as well as for 
oligonucleotides combined with anticancer drugs 5-fluorouracil, gemcitabine, paclitaxel, 
vinorelbine ditartrate, or irinotecan.142 A recent report describes tenfold increased 
doxorubicin efficiency when codelivered in liposomes with siRNAs targeting antiapoptotic 
cellular defense and multidrug-resistance, compared to free and liposomal doxorubicin.143 
However, the major obstacles constructing nanocarriers for drug delivery applications are a 
lack of biocompatibility and biodegradability as well as the stimuli-responsive release 
triggered by physiological microenvironment at the site of disease. 
1.3.5 Self-Assembling Peptides – Promising Drug Carriers 
Peptides are very promising candidates to be used for self-assembling nanostructures for 
biomedical applications. Increasing understanding of protein folding mechanisms facilitates 
rational design of peptide sequences to self-assemble into predefined structures. The 
assembly process is driven by inter- and intramolecular interactions such as electrostatic and 
hydrophobic interactions, hydrogen bonds, π–π stacking, and van der Waals forces. Peptides 
were created to self-assemble into micelles,144,145 vesicles,11,146,147 fibers,148,149 and spheres.2,31 
The relatively low synthesis effort and the extraordinary versatility of designs, based on 
amino acid sequences are just two among other advantages over other materials. 
Furthermore, naturally occurring peptide sequences with defined secondary structures, such 
as β-sheet and α-helices, can be adapted for creating de novo peptides. Being considered as 
inherently biocompatible and biodegradable, they are predestinated for biomedical use.19,146 
For instance, drug delivery carriers are usually complex systems requiring diverse 
functionalities to achieve high efficacy. Their formation often involves complicated 
procedures with multiple components and post-assembly modifications. Using the 
outstanding properties of designable peptide sequences it is possible to unify all desired 
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functions within one multifunctional peptide sequence, thereby obviating complex 
formulation work. In addition, the self-assembly process become very defined by using only 
one type of amphiphile enabling production of uniform constructs necessary to provide 
distinct properties and/or effects. 
1.4 MRI Contrast Agents 
Magnetic resonance imaging (MRI) is a widely used diagnostic tool in modern medicine to 
visualize structures of the body. MRI is a noninvasive method with no radiation harm, in 
contrast to computer tomography (CT), providing excellent spatial resolution in a sub-
millimeter range. It is based on the nuclear magnetic resonance (NMR) of water protons in 
different body environments. To increase the contrast chemical contrast agents (CAs) are 
extensively used in clinical imaging. Most common CAs are based on paramagnetic transition 
metals, predominantly gadolinium (Gd), and superparamagnetic iron oxide nanoparticles 
(SPIONs). Using paramagnetic transition metal-based CAs the MRI signal intensity is 
increased by decreasing the longitudinal relaxation time (T1) of water protons in close 
proximity to the CA. Gadolinium is a trivalent lanthanide and reveals high complexing 
abilities to biomolecules in the body, which results in high toxicity of aqueous gadolinium. 
To avoid toxic effects, gadolinium is sequestered by acyclic and macrocyclic 
polyaminocarboxylic acids, such as diethylenetriaminepentaacetic acid (DTPA) and 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).150 To date, eleven MRI 
CAs have been approved by the FDA, typically having r1 relaxivities of around 4–5 mM-1s-1 at 
1.5 T.151 Nine are gadolinium-based (Figure 8), only two were built from other metals; one 
from iron nanoparticles, one from manganese complexes. However, neither of these 
nongadolinium contrast agents are commercially available anymore.152 Typically 
administered doses for standard clinical applications are 0.1–0.3 mmol kg-1, requiring 
injection of several grams of CA.152 To lower the necessary dose and monitor physiologic 
conditions at target pathological sites in the body, functional high-relaxivity CAs are 
essential. To increase the relaxivity of contrast agents, numerous parameters and influence 
factors have to be considered, effectively described by the Solomon-Bloembergen-Morgan 
theory.153-157 
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Figure 8. FDA-approved commercial MR contrast agents based on macrocyclic and linear 
polyaminocarboxylate-gadolinium complexes.150	
1.4.1 Solomon-Bloembergen-Morgan Theory 
The quality of a contrast agent is determined by its relaxivity. It describes the ability to 
increase relaxation rates of water at given concentrations of paramagnetic metal ions, mostly 
Gd. The contributions of diamagnetic and paramagnetic relaxation rates to the observed 
relaxation of water protons are additive and given by Equation 1.158 
!!! !"# = !!! ! + !!! ! (1) 
(1/Ti)obs is the observed water relaxation rate; subscript d stands for diamagnetic and 
subscript p stands for paramagnetic. The paramagnetic contribution to the relaxation rate is 
linearly dependent on the concentration of the paramagnetic species. The relaxivity (ri, 
i=1,2) is defined as the slope of (1/Ti) versus Gd-concentration (Equation 2).158 !!! !"# = !!! ! + 𝑟! 𝐺𝑑  (2) 
Two components contribute to the paramagnetic relaxation enhancement: the inner-sphere 
relaxation of the water directly coordinated to Gd(III) and the outer-sphere water in the 
second coordination sphere including the bulk water. If the water exchange rate at the metal 
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center is fast, or the mean residence time (τM) is low (τM ≪T1m), the contrast enhancement 
comes from the increase of the relaxation rate (1/T1m) of the coordinated water molecules.158 !!! = 𝑞𝑃! !!!!!!! (3) 
Pm is the water bound to the metal center (mole fraction), q is the number of bound water 
molecules per metal ion and τM is the mean water residence time at the inner-coordination 
sphere (τM is the reciprocal of the water exchange rate, kex). The relaxation rate is therefore 
directly related to the number of bound water molecules. T1 for the dipol-dipol (DD) 
relaxation mechanism is described by the paramagnetic relaxation theory by Solomon-
Bloembergen-Morgan (Equation 4).151 
!!!!! = !!" !!!!!(!!!)!!!!!"!!! !!!!!!!!!!!!! + !!!!!!!!!!!!!  (4) 
γ is the nuclear gyromagnetic ratio, g stands for the electronic g-factor, µB is the Bohr 
magneton, rGd–H is the electron spin water nuclear spin distance, ωI is the nuclear precession 
frequency, ωS is the electron precession frequency and τci are dipole-dipole relaxation 
correlation times. For optimizing relaxivities of CAs τci become important. It can be 
influenced by modulating the rotational correlation time (τR) and τM.158 !!!" = !!! + !!!" + !!! (5) 
The theory demonstrates the interplay of numerous of factors to be considered when 
designing new or optimizing current contrast agents. Extracting the most influencing 
parameter, which can be optimized for engineering high relaxivity CAs, we obtain three 
factors: the molecular tumbling (τR), the hydration number (q) of the metal ion, and the 
solvent exchange rate (τM). Figure 9 shows a schematic view of the parameter in the case of 
Magnevist. 
	
Figure 9. Key factors that influence the relaxivity of a contrast agent. To obtain a higher relaxivity the 
water exchange rates have to be increased and the molecular tumbling decreased compared to 
commercial contrast agents.151 
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Molecular tumbling, which is in the picosecond range for commercial CAs,151 is decreased by 
increased molecular weights of the complexes. Therefore, retarding the rotational motion of 
complexes increses τc. This can be achieved by coupling complexes to macromolecules such 
as polymers or proteins. Lauffer et al. pioneered this approach by conjugating DTPA-Gd and 
ethylenediaminetetraacetic acid-Gd (EDTA-Gd) complexes to bovine serum albumin (BSA) 
and bovine immunoglobulin G (IgG) yielding a significant higher relaxivity.159,160 Coupling 
Gd-complexes to linear or dendritic polymers revealed the same tendencies as found for 
protein conjugates.161-163 Interestingly, the rigidity and nature of polymers had a significant 
effect on r1. Linking complexes to more rigid polymers resulted in substantially higher 
contrast enhancement compared to more flexible constructs of the same molecular weight. 
DTPA-Gd, for instance, conjugated to poly(propylene imine) (PPI) dendrimers was found 
to reveal increasing relaxivities with increasing generations of the dendrimer due to growing 
rigidity and reached an r1 of 19.7 mM-1s-1 in the fifth generation, compared to 4.7 mM-1s-1 for 
DTPA-Gd.164 In contrast, flexible polyethylene glycol (PEG) had almost no retardation effect 
on the rotational motion, thereby r1. On the other hand, conjugation to macromolecules may 
interfere with the water exchange at the metal ion and thus, lead to lower relaxivity. Studies 
have shown that introducing PEG to a Gd-chelates with a hydration number of two (q = 2) 
led to a decrease of q to one compensating the decreased tumbling yielding r1-values 
comparable to the nonconjugated analog.165 Throughout the years of extensive research in 
this field a large variety of Gd-chelates evolved ranging from linear and cyclic 
polyaminocarboxyl derivates to bifunctional chelates bearing functional groups such as 
anhydride, isobutyl chloroformate, isothiocyanate, or amine.166 
1.4.2 Responsive Contrast Agents 
The main influence factors, which are tuned and optimized to increase contrast can be 
exploited to develop functional CAs responsive to abnormal conditions in the body such as; 
metals, pH, redox state, temperature, light, or enzyme activity. The signal enhancement of 
responsive contrast agents (sometimes also called “smart” or “activatable” contrast agents) 
depends not only on the relaxivity but also on the concentration, which allows for two 
approaches: targeting the region of interest and responsive relaxation enhancement at 
conditions of the region of interest. Reduction-responsive contrast agents were constructed 
based on different oxidation states of a free radical or metal ion of the CA. Paramagnetic 
nitroxide radicals were shown to lose their relaxation properties when reduced to the 
hydroxylamine analog.167 Another example comprises manganese (Mn) chelates, which 
revealed increased relaxivity in their reduced state (Mn(II)) compared to the oxidized 
chelates (Mn(III)).168 Redox states can also lead to changes in water coordination and 
accessibility of the metal center. For instance, a hypoxia-sensitive CA was developed bearing 
nitrobenzene, reducible to an aminobenzene, which leads to protonation of a gadolinium-
coordinating secondary amine in the chelate. Thus, the amine is no longer coordinated to the 
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metal center, which increased the hydration number, thereby r1.169 A further example 
describes the change in rotational motion upon oxidation demonstrated for thiol-containing 
Gd-chelates forming disulfide coupling with cysteines of albumin.170 For the detection of 
acidic compartments, in order to recognize cancer or inflammations, or to visualize drug 
delivery, pH-sensitive CAs are of high importance. A convenient way to develop pH-
responsive contrast agents is the dissolvation or degradation of assembled materials when 
acidified. For instance, pH-sensitive liposomes loaded with Gd-chelates released its payload 
when acidified, decreasing the relaxation time (T1), thus increasing r1.171 In vivo diagnosis of 
acidic tumors were performed using imidazole-containing micelles with incorporated Gd-
chelates, which disassemble and increase r1 upon acidification.172 Although, many responsive 
CA systems have been developed to date most of them do not show high relaxivity 
(>30 mM-1s-1) thus lack properties to significantly increase contrast and decrease limit of 
detection for diagnostic purposes. 
1.5 Peptide Synthesis 
Peptide synthesis describes the chemical synthesis of peptides by serially coupling desired 
amino acids to obtain a defined peptide sequence. For research and development purposes 
the synthesis is in almost all cases performed on solid state. Only when synthesizing on large-
scale liquid phase synthesis is used. 
1.5.1 Solid Phase Peptide Synthesis 
Solid phase peptide synthesis (SPPS) allows the construction of defined peptide sequences 
by successive coupling of amino acids to a peptide chain covalently attached to insoluble 
resin beads. The method was first introduced by Merrifield in 1963, using crosslinked 
polystyrene as the insoluble carrier and a t-butoxy-carbonyl/benzyl (tBoc/Bzl)-strategy.173 
The first amino acid was attached to the resin by an acid-labile linker having the α-amino 
position (Nα) protected by tBoc and the side chains protected by a more acid stable Bzl 
protecting group. To couple further amino acids the N-terminal amine was deprotected 
using trifluoroacetic acid (TFA). After several neutralization and washing steps, the second 
amino acid was coupled by the formation of an amide bond in the presence of an activator. 
Repetition of this procedure (deprotection and coupling) led to the growth of the desired 
peptide on the resin. After coupling the last amino acid the final peptide was obtained by 
simultaneous deprotection of the side chains and cleavage from the resin by treatment with 
hydrogen fluoride (HF), which is highly toxic, thus needs special equipment and handling. 
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In 1970, Carpino and Han introduced 9-fluorenylmethyloxycarbonyl (Fmoc) as a base labile 
Nα-protecting group (Scheme 1). Eight years later the Fmoc/tBu strategy was proposed by 
Meienhofer, using acid labile tButyl or tBoc for the protection of amino acid side chains and 
Fmoc to protect the Nα-position.174 This new strategy offered a mild alternative to the 
tBoc/Bzl-strategy by eliminating the need of HF for cleavage and evolved to the most used 
solid phase peptide synthesis strategy over the years. Before presenting solid supports, 
linkers, and coupling reagents (activators), the general process of solid phase peptide 
synthesis is briefly described:  
The first step is the swelling of the linker-functionalized solid support in an appropriate 
solvent to offer the best possible accessibility of the functional groups to the first reagent. 
Then, the first amino acid is coupled to the linker in the presence of an activator followed by 
several washing and filtration steps to remove all non-reacted amino acids from solution 
before further couplings (Scheme 2A). The remaining free amines on the resin are then 
reacted with acetic acid anhydride (capping) to avoid reaction with any further amino acids 
in the following steps. The Fmoc in Nα-position is deprotected by addition of piperidine, 
followed by washing and filtration steps as for the first coupling (Scheme 2B). The peptide is 
elongated repeating the described steps until the desired peptide sequence is obtained 
(Scheme 2C,D). For the cleavage and simultaneous deprotection of the side chains, a 
mixture of mainly TFA with water and scavengers (“cleavage-cocktail”) is used (Scheme 2E). 
The final peptide is then separated from the resin by filtration and precipitated in diisopropyl 
ether. 
	
Scheme 1. Fmoc protection (red) of an amino acid using fluorenylmethyloxycarbonyl chloride 
(Fmoc-Cl) (A). Deprotection occurs via nucleophilic attack with piperidine to obtain the free amine 
of the amino acid (B). 
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1.5.1.1 Solid Supports and Linkers (Fmoc Strategy) 
The requirements for the solid support (resin) are: stability to all solvents used during the 
synthesis, deprotection, and cleavage; mechanical stability towards the filtration steps; low 
crosslinking to allow good accessibility; and good swelling properties. Furthermore, the resin 
should be equipped with functional groups enabling chemical coupling to linkers. To date, 
three types of resins are mainly used being polystyrene (PS), polyethylene glycol (PEG) 
functionalized PS, and PEG-based resins. Swelling and loading performances of commonly 
used resins are summarized in a recent publication of Sheldon et al.175 The linker provides 
reversible binding sites for coupling of the first amino acid to the solid support. Linkers are 
designed to be resistant to the coupling and deprotection of amino acids during synthesis but 
cleavable under well-defined conditions. Moreover, depending on the chemical structure and 
the cleavage mechanism of the linker peptides can be obtained with a variety of C-terminal 
functionalities. Most common C-termini are amides and acids, as these are natural peptide 
end groups. But also, aldehydes, alcohols, hydrazides, thioesters and other functionalities are 
accessible through different linker designs. For Fmoc-SPPS, 4-alkoxybenzyl alcohol-type 
linker (Wang-linker) and chlorotrityl chloride linker (Barlos-linker/resin) are frequently 
used for synthesizing peptide acids. To obtain peptide amides, the benzhydryl-type linker 
(Rink amide linker) is predominantly used.175 
	
Scheme 2. General procedure for solid phase peptide synthesis using the Fmoc-strategy. First amino 
acid is coupled to the resin via an acid cleavable linker (A), Fmoc deprotection by piperidine (B), 
amino acid coupling supported by activators (C), capping of non-reacted amines by acetic acid 
anhydride (Ac2O) and deprotection of Nα by piperidine (D), and cleavage and deprotection with a 
TFA-based cleavage cocktail containing scavengers (E) (the composition is dependent on amino acids 
present in the particular sequence). 
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1.5.1.2 Coupling Reagents (Activators) 
Activation of the C-terminal acid is required to form peptide bonds between individual 
amino acids. This was originally achieved by using N,N’-dicyclohexylcarbodiimide (DCC) or 
N,N’-diisopropylcarbodiimide (DIC). Due to the tendency of these activators to racemize 
the amino acids new, racemization suppressant activators were developed such as 1-
hydroxybenzotriazole (HOBt), 1-hydroxy-7-azabenzotriazole (HOAt), 2-(1H-benzotriazol-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-
yl)-N,N,N′,N′-tetramethyluronium hexafluorphosphate (HATU), benzotriazol-1-yl-
oxytripyrrolidino-phosphonium hexafluorophosphate (PyBOP), and 2-(6-chlor-1H-
benzotriazol-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) (Figure 
10).176 
	
Figure 10. Different activators used in SPPS to form peptide bonds suppressing racemization of 
amino acids as observed for initially used DCC and DIC. 
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1.6 Aim of the Thesis 
The overarching goal of the present thesis is the de novo design and synthesis of responsive 
and functional amphiphilic peptides as molecular building blocks to self-assemble into smart 
nanoparticles for biomedical applications. These encompass two functional classes: 
diagnostic nanoparticles and therapeutic nanoparticles.  
In the past decades numerous drug- and gene-delivery carriers have been developed to 
increase therapeutic efficacy, decrease drug doses, and minimize side effects. While drug 
delivery carriers for small molecule drugs became well established, noncytotoxic gene 
delivery remains a major challenge. Additionally, emerging beneficial synergistic effects, 
combining therapeutic drugs and/or genes created a tremendous demand for sophisticated 
and responsive codelivery systems. Similarly, current diagnostic nanoparticles still lack high 
sensitivity and specificity. There is, for instance, a great need for highly sensitive and 
responsive MRI contrast agents for early diagnosis of diseases. 
For these reasons, the scope of this thesis addressed the elaboration of functional self-
assembled peptide nanoparticles for diagnostic and therapeutic applications. A first strategy 
for the development of diagnostic tools encompassed the incorporation of gold nanoparticles 
within self-assembled peptide nanoparticles. These offer the additional feature of being 
responsive to external trigger due to their thermoplasmonic properties. A second strategy 
aimed for the development of highly active MRI contrast agents, built from novel gadolinium 
complexes, in conjunction with responsive peptides to provide targeted contrast 
enhancement in tumor tissue for early diagnosis of cancer. Another scope of the present 
dissertation was the creation of a purely peptidic, stimuli-responsive small molecule 
drug/antisense oligonucleotide codelivery system readily taken up by cells to achieve high 
therapeutic efficacy. A further goal comprised the construction of a peptidic gene 
transfection carrier for the delivery of plasmid DNA. 
For tailoring amphiphilic peptides lysines, histidines, and cysteines are of particular interest 
due to their specific chemical and physicochemical properties. They enable distinct 
interactions not only to payloads but also to physiologically relevant environments. 
Accumulation of various individual characteristics into one single peptide sequence while 
minimizing complexity of the assembly process to achieve smart nanomaterials, which fulfill 
application-oriented requirements, is very desirable.  
Physicochemical characterization and biologic evaluation of the created nanoparticles 
provided essential information about their applicability and compatibility as well as about 
their self-assembling behavior. This allowed for tuning the peptides to assemble into smart, 
responsive, biocompatible, and biodegradable nanomaterials suitable for these applications. 
Straightforward rational design incorporating specific function to the sequences by point 
mutations served as a promising strategy to achieve these goals. 
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Chapter 2 
2 Self-Assembled Peptide Nanoparticles Used as 
a Template For Ordered Gold Nanoparticle 
Superstructures 
In this chapter, the formation of ordered peptide–gold nanoparticle superstructures via a 
two-step procedure is described. The particles are thoroughly analyzed and the 
underlying structure is discussed based on studies on planar coatings. Moreover, the 
composite nanoparticles are tested on the effect of NIR-illumination. 
	
	
Reproduced in part with permission from Colloids and Surfaces B, Biointerfaces: 
de Bruyn Ouboter, D.; Schuster, T. B.; Sigg, S. J.; Meier, W. P. Self-assembled peptide beads used as a 
template for ordered gold nanoparticle superstructures. Colloids Surf., B 2013, 112, 542-547. © 2013, 
with permission from Elsevier. 
	
Scheme 3. Self-assembled beads from the amphiphilic peptide AcX3gTC are able to embed gold 
nanoparticles within their structure and thus act as a 3D template.	 	
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2.1 Abstract 
Using peptide-based materials to tailor self-assembled, nanoscaled hybrid materials with 
potentially high biocompatibility/biodegradability is gaining importance in developing a 
broad range of new applications, in areas such as diagnostics and medicine. Here, we 
investigated how the self-assembly capacity of self-assembling, purely peptidic amphiphiles 
can be used to create organized inorganic materials, i.e. gold nanoparticles. A nanoparticle-
forming, amphiphilic peptide Ac-[K(Ac)]3-[W-DL]3-W-NH2, containing acetylated (Ac) L-
lysine (K), L-tryptophan (W), and D-leucine (DL), was C-terminally modified with a cysteine 
(C) and linked to gold nanoparticles. Subsequent peptide-driven self-assembly of the 
peptide-coated gold nanoparticles with increasing water content led to controlled 
aggregation of the gold-core micelles, forming composite peptide–gold superstructures. The 
individual gold nanoparticles did not agglomerate but were separated from each other by a 
peptide film within the composite material, as revealed by electron microscopy studies. 
Structural investigation on 2D template-stripped gold demonstrated the ability of the 
peptides to form self-assembled monolayers. Structural elements of β-turns and weak 
hydrogen bonding of the hydrophobic moiety of the peptide were evident, thereby 
suggesting that the secondary structure remains intact. 
2.2 Introduction 
Exploiting the beneficial properties of two distinct nanomaterials in one hybrid can lead to 
advanced functional materials, thereby opening the door to a broad range of new applications 
in diagnostics and medicine. Materials based on colloidal, inorganic nanoparticles that 
exhibit exceptional properties177,178 have led to the development of magnetic nanoparticles,179 
biosensors,180 tools for bioimaging,181,182 and MRI contrast agents,183,184 thereby improving the 
areas of medical imaging and diagnostics. The use of peptides to design tailor-made, tunable, 
responsive, and nanoscaled materials185 has also become popular and is particularly 
advantageous in medical applications such as biodegradable implant interfaces,186 scaffolds 
for regenerative tissue growth,187 and nanosized drug delivery vehicles.188 Great potential 
derives from the benefits that accompany peptide-based materials featuring a multitude of 
functionalities and unique secondary structures based on controllable primary sequences and 
environmental conditions. In self-assembled structures, peptides can act as specific ligands or 
targeting moieties. In addition, peptides and proteins are built up from a library of 20 α-
amino acids (AAs), which are generally considered to be biocompatible and biodegradable, 
although some toxic AAs are known.189,190 Therefore, it is not surprising that peptides have 
been used to form fascinating hierarchical inorganic nanomaterials. There are many examples 
of peptides, containing a thiol group to bind gold and exhibiting a distinct affinity, such as 
CALNN (referring to its AA sequence), which was reported to form self-assembled 
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monolayers (SAM) on gold nanoparticles (Au-NPs).191 Aili et al. demonstrated a new route 
for nanofabrication by the association of functionalized Au-NPs via a polypeptide in a 
folding-dependent manner and well-defined interparticle spacing.192 By using the peptide 
AG4 as a reducing agent to guide the nucleation and growth of the Au-NPs, self-assembled 
hybrid spheres were obtained. It was noted that, the primary sequence of the peptide, 
especially AA containing aromatic functional groups, altered the assembly.193 This strong 
dependency on changes in the peptide conjugates towards the formation of spherical Au-NP 
superstructures was also observed by Song et al.194 
Recently, it was shown that synthetic, short, purely peptidic amphiphiles can be used to 
produce a variety of self-assembled structures – such as micelles and fibers,148 vesicles,28 and 
peptide nanoparticles (multicompartment micelles)29,30 – in a well-controlled manner. A 
truncated version of gramicidin A (gA) was used for the hydrophobic moiety of the 
amphiphiles (gT, Table 2). The β-helical structure of gA is unique and defines the 
hydrophobic character.195  
Table 2. Codes and Sequences of Amphiphilic Peptides Used to Study the Formation of 
Peptide–Gold Nanoparticles Superstructures. 
code sequence 
Gramicidin A HCO-V-G-A-DL-A-DV-V-DV-[W-DL]3-W-NHCH2CH2OH 
-gT  -[W-DL]3-W-NH2 
AcX3gT  Ac[K(Ac)]3-[W-DL]3-W-NH2 
AcCX3gT  Ac-C-[K(Ac)]3-[W-DL]3-W-NH2 
AcX3gTC  Ac[K(Ac)]3-[W-DL]3-W-C-NH2 
 
The hydrophilic, peptidic backbone is hidden within the helix, as the hydrophobic 
tryptophan (W) and leucine (DL) side chains shield it. Thus, this structure as a purely 
peptidic hydrophobic sequence allows the construction of an amphiphile. The hydrophilic 
sequence consists of oligolysine, either acetylated (X) or native (K). The uncharged peptides 
AcX3gT as well as AcX3gTC (with a C-terminal cysteine, Table 2) form spherical 
nanoparticles in aqueous solution. Their size can be controlled within a diameter range of 
260–800 nm by means of the initial peptide concentrations prior to the self-assembly 
process.30 Therefore, the secondary structure of the amphiphilic molecule is essential. It was 
shown that if the three D-leucines are replaced by L-leucines, peptide nanoparticles will not 
be formed.31 A hierarchical organization of micelle-like structures within the peptide 
nanoparticles was found and the structures assigned to multicompartment micelles 
(MCM).30  
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In this study, we focused on structural elements; that is, how the self-assembly ability of short 
and purely peptidic amphiphiles can be used in interaction with gold nanoparticles (Au-NPs) 
to obtain hierarchically organized composite peptide–gold NPs, i.e. the peptide would act as 
a template for the ordered assembly of Au-NPs to create a new composite material. 
2.3 Results and Discussion 
2.3.1 Peptide Nanoparticles – Templates for 3D Incorporation of 
Gold Nanoparticles (Au-NPs) 
The objective was to use the peptide nanoparticles assembly as a template for the 
organization of Au-NPs therein. As illustrated in Scheme 4, AcX3gT self-assembles in 
peptide nanoparticles with a multicompartment micelles (MCM) structure.29,31 Therefore, 
we included a thiol functional group (cysteine) at the hydrophobic C-terminal end of the 
peptide for a possible connection of the peptide to the Au-NPs (AcX3gTC, Table 2). 
Ethanolic peptide solution was pretreated with DTT to avoid disulfide formation of the 
peptide before being mixed together with Au-NPs (8.1 ± 1.0 nm) for 6 h. Therefore, an 
excess of peptide (102×) was provided to enable a maximum coverage of Au-NPs. Afterwards 
the Au-NPs were separated from free, unbound peptide in the solution by dialysis in 50% 
ethanol (no self-assembly30) and subsequently dialyzed against water, which induced the self-
assembly process revealing composite peptide–gold nanoparticles. The resulting solution 
was typically a turbid, reddish solution with observable sedimentation.  
	
Scheme 4. Illustration of formation processes: micelle and peptide nanoparticle formation (A), 
coating of gold nanoparticles with the peptide AcX3gTC and subsequent formation of composite 
peptide–gold nanoparticles enabled by the self-assembly features of the peptide (B), and formation of 
a peptide SAM on template-stripped gold using AcCX3gT (C). 
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Figure 11. SLS analysis (Zimm plot) of CP-Au-NPs revealing an Rg of 124 ± 9 nm (A). DLS analysis 
(D-II, cumulant fit) resulting in an Rh of 154 ± 16 nm (B). 
Analysis was performed by static and dynamic light scattering (SLS and DLS), transmission 
electron microscopy (TEM), and scanning electron microscopy (SEM). SLS provided a 
radius of gyration (Rg) of 124 ± 9 nm, while the hydrodynamic radius (Rh) was calculated to 
154 ± 16 nm (Figure 11), thus resulting in a ratio Rg/Rh of 0.80 – close to the theoretical 
value of a solid sphere (0.775). The detected particles were thus far bigger than the 8.1 nm 
Au-NPs. As shown in Figure 12A, small particles showed homogenously distributed Au-NPs 
in a dense arrangement within the peptide nanoparticles. However, the formed nanoparticles 
also exhibit a certain size distribution and variation in Au-NP density (Figure 12C), which 
may require isolation of a particular species depending on the application. 
	
Figure 12. TEM micrographs of self-assembled CP-Au-NPs showing: dense packing of Au-NPs 
within particles (A, B, D) and an overview of size distribution and gold particle distribution (C, E).  
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It can be clearly seen that Au-NPs did not aggregate within the peptide nanoparticles but 
were separated by the peptide material. The thickness of the peptide layer around the Au-
NPs, which was measured on its edge, was 1.3 ± 0.6 nm. Considering the length of the 
peptides of around 1.6 nm, this indicates peptide monolayers around the Au-NPs, i.e. Au-
NPs which are separated from each other by peptide double layers, though a partial overlap 
cannot be excluded.28 These expected findings are consistent with the MCM structure of the 
peptide nanoparticles. SEM showed similar particle sizes compared to TEM micrographs 
(Figure 13). These findings allow the description of a possible formation process. Via the 
described two-step, one-pot protocol, first, Au-NPs were coated by AcX3gTC in ethanol 
solutions, which was followed by the self-assembly of the obtained gold-core micelles into 
composite peptide-gold nanoparticles (CP-Au-NPs) during dialysis against water (Scheme 
4). The self-assembly capacity of the peptidic amphiphiles acted as a template for 3D 
organization of Au-NPs.  
	
Figure 13. SEM micrograph of composite peptide gold nanoparticles revealing similar sizes and 
morphologies compared to TEM pictures. 
2.3.2 Model Studies – AcCX3gT Peptide Films on Planar Gold 
Surfaces 
We investigated 2D peptide films on a planar gold surface to deduce more information about 
peptide gold interaction and the ability of the peptides to form monolayers. As a gold surface, 
template-stripped gold (TSG) was used, which is known to exhibit a very smooth surface.196 
To access defined peptide monolayers we used the Langmuir-Blodgett (LB) technique. It 
was therefore judged to be prudent to use AcCX3gT instead of AcX3gTC, to be able to 
transfer the LB film – in which amphiphilic peptides are orientated with the more hydrophilic 
sequence (AcCX3) towards the water and the hydrophobic sequence (gT) towards the air – 
covalently onto TSG. The possibility to substitute AcX3gTC by AcCX3gT was further 
supported by their similar self-assembly properties.29,31 An isotherm of AcCX3gT is shown in 
Figure 14. Peptide films were produced by the LB technique, transferred onto freshly cleaved 
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TSG and subsequently analyzed by atomic force microscopy (AFM). Figure 15 presents an 
AFM image of a transferred AcCX3gT film. The films showed a very homogenous, 
featureless, and smooth surface. A slightly rougher surface compared to bare TSG indicated 
deposition but also illustrated the excellent quality of the peptide films. The partial removal 
of the peptide film upon scratching with the AFM tip and subsequent scanning further 
indicated the successful transfer of the LB film to the solid substrate and revealed a film 
thickness of about 1.2 nm. Considering the length of a molecule to be 1.6 nm, this value 
might arise from either low surface coverage (unlikely for LB transfer at high surface 
pressure) or a tilt angle of approximately 40° (Figure 15, wild-type gA at the air–water 
interface: 30°).197  
	
Figure 14. Isotherm of AcCX3gT peptide. The mean molecular area (MmA) of 196 ± 3 Å2/molecule 
arises from extrapolation to zero surface pressure, which reflects a helix radius (r) of 7.9 Å and is 
consistent with literature values for the gA helices.195,197 
	
Figure 15. AFM image of a partly removed AcCX3gT film on a Si-wafer via scratching shows a 
thickness of 1.2 nm (a). Tilt angle based on a peptide length of 1.6 nm (b). 
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Additionally to LB transfer, we investigated the formation of peptidic self-assembled 
monolayers (SAM). In this technique, peptides are not compressed into a 2D arrangement as 
in the LB technique, but will have to arrange themselves onto the gold substrate without 
external pressure, which corresponds more to the processes of peptide adsorption onto Au-
NPs from solution. 
Using the thiol-functionality for the formation of a SAM is best known for alkyl chains, but 
also the rod-like structure of the hydrophobic gT-trunk is expected to form an ordered 
alignment.198 The TSG samples were then immersed in an AcCX3gT ethanolic solution for 
12 h and analyzed by AFM. The resulting thin films showed very smooth surfaces, similar to 
LB-films, as illustrated in the height profiles in Figure 16. 
	
Figure 16. AFM images and corresponding height profiles of (A) template-stripped gold (TSG) (B) 
AcCX3gT monolayer on TSG via Langmuir-Blodgett transfer (πTR = 25 mN/m) and (C) AcCX3gT 
monolayer on TSG via immersion. 
Adsorption of AcCX3gT on gold was monitored by a quartz crystal microbalance  (QCM). 
The mass kept increasing up to 150 ng/cm2 while dissipation stayed constant (Figure 17) 
indicating a surface adsorption of dissolved peptide molecules to form a rigid, thin film 
(~1.5 nm), not removable by washing. The binding of the N-terminally functionalized purely 
peptidic amphiphiles to gold demonstrates the capacity of the peptides to bind to gold as 
with the well-known thiol–gold bonds.199 
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Figure 17. QCM analysis of AcCX3gT. QCM frequency shift (blue) and dissipation (red) of an 
ethanolic peptide solution (A). Mass adsorption via Sauerbrey, which translate into a thickness, 
assuming a density of the peptide layer of 1 g/cm3 (B). 
To gain further information on the obtained film, we performed IR, i.e. polarization 
modulation infrared reflection absorption spectroscopy (PM-IRRAS) measurements on two 
samples (from LB transfer and immersion techniques). First, the results prove the presence 
of a peptide film on the TSG (Figure 18). Second, the amide I adsorption of both samples at 
1662–1675 cm-1 (weak signal at ~1612 cm-1) differs significantly from the known spectra for 
gA conformations, and also from the random coil spectra (~1630–1640 cm-1).200-202 
Nevertheless, the amide I adsorption was related to β-turns and weak hydrogen bonding.200 
In addition, the circular dichroism spectra, presented earlier,31 support its helical 
configuration, with a maximum at 223 nm, related to the [W-DL]3-W moiety, that was also 
found for L- and D-amino acids containing cyclic peptides.203 Therefore, based on similarity 
with these peptides, we propose the secondary structure of gT to contain a β-turn stabilized 
by intramolecular hydrogen bonding. 
	
Figure 18. PM-IRRAS: Immersion in ethanolic AcCX3gT peptide solution (solid) and AcCX3gT LB-
film (dashed). 
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However, caution must be taken when transferring results from a planar surface to the Au-
NPs and vice versa based on the differences in curvature. Nevertheless, because the results 
from IR measurements for transferred LB-films are comparable with the results for self-
assembled monolayers, it indicates that covalent adsorption without the deformation of the 
peptide secondary structure is possible.  
To assess the responsiveness of the incorporated gold nanoparticles to near infrared (NIR) 
irradiation composite peptide–gold nanoparticles were exposed to 805 nm laser light. The 
particles were monitored on their size distribution using DLS at 90°. However, irradiation 
with 100 mW 805 nm laser light for up to 1 h did not significantly affect the sizes of the 
particles, thus indicating no decomposition in the tested range (Figure 19). This can be 
attributed to the relatively low intensity and the wavelength, which is at the border of visible 
light to infrared, necessary to not cause harm to the skin and for a deeper penetration to soft 
tissue. 
	
Figure 19. Hydrodynamic diameters of CP-Au-NPs irradiated with 805 nm laser light obtained from 
DLS measurements. 
2.4 Conclusion 
C- or N-terminal modification of the nanoparticle forming peptide AcX3gT with cysteine 
(AcX3gTC and AcCX3gT) led to similar self-assembly behavior and allowed the linkage of 
the peptide to gold. A homogenous, 2D peptide alignment was illustrated by transferred 
monolayers and, similarly, via immersion and the formation of peptide SAMs. For the 
secondary structure of the hydrophobic gT region, a β-turn and intramolecular hydrogen 
bonds were proposed, these being assigned for both films: the transferred LB and the SAM. 
The latter indicates the possibility that, also on the Au-NP, an intact configuration remains, 
which is also supported by the thickness of the peptide layer around the Au-NP within the 
nanoparticles. 
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An in situ reaction with Au-NPs allowed us to transfer the self-assembly properties of the 
peptide to new, composite material, which led to the aggregation of the gold-cored micelles 
forming particles of sizes similar to the original peptide nanoparticles without gold. We 
showed that the newly formed composite peptide–gold nanoparticles are densely packed, but 
the individual gold nanoparticles remain separated by a thin peptide bilayer. The newly 
formed CP-Au-NPs may find application as a drug delivery system using the intrinsic 
thermoplasmonic properties of the incorporated gold nanoparticles to trigger release of 
payload. Furthermore, the created CP-Au-NPs lay the basis for the development of 
theragnostic agents exploiting the intermicellar space to incorporate payloads while the 
attenuation of X-rays by the gold nanoparticles enables high contrast in computer 
tomography. However, further investigation and optimization of the system is required to 
exploit full potential. 
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Chapter 3 
3 Stimuli-Responsive Codelivery of 
Oligonucleotides and Drugs by Self-Assembled 
Peptide Nanoparticles 
This chapter aims for the rational design of responsive peptide nanoparticles for 
simultaneous delivery of antisense oligonucleotides and small molecule drugs. It includes 
the design, synthesis, and nanoparticle formation as well as the loading and controlled 
release of the payloads upon a reductive trigger. Furthermore, the potential of the novel 
nanoparticles is demonstrated by the delivery of a clinically relevant drug. 
 
Reproduced in part with permission from Biomacromolecules: 
Sigg, S. J.; Postupalenko, V.; Duskey, J. T.; Palivan, C. G.; Meier, W. Stimuli-Responsive Codelivery of 
Oligonucleotides and Drugs by Self-Assembled Peptide Nanoparticles. Biomacromolecules 2016, 17, 
(3), 935-945. © 2016 American Chemical Society.  
	
Figure 20. Coloaded reduction-responsive peptide nanoparticles internalize to cells. In contact with 
elevated glutathione levels in the cytosol the peptide nanoparticles disintegrate and release their 
payloads. 
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3.1 Abstract 
Ever more emerging combined treatments exploiting synergistic effects of drug combinations 
demand smart, responsive codelivery carriers to reveal their full potential. In this study, a 
multifunctional stimuli-responsive amphiphilic peptide was designed and synthesized to self-
assemble into nanoparticles capable of co-bearing and -releasing hydrophobic drugs and 
antisense oligonucleotides for combined therapies. The rational design was based on a 
hydrophobic L-tryptophan-D-leucine repeating unit derived from a truncated sequence of 
gramicidin A (gT), to entrap hydrophobic cargo, which is combined with a hydrophilic 
moiety of histidines to provide electrostatic affinity to nucleotides. Stimuli-responsiveness 
was implemented by linking the hydrophobic and hydrophilic sequence through an artificial 
amino acid bearing a disulfide functional group (H3SSgT). Stimuli-responsive peptides self-
assembled in spherical nanoparticles in sizes (100–200 nm) generally considered as 
preferable for drug delivery applications. Responsive peptide nanoparticles revealed notable 
nucleotide condensing abilities while maintaining the ability to load hydrophobic cargo. The 
disulfide cleavage site introduced in the peptide sequence induced responsiveness to 
physiological concentrations of reducing agent, serving to release the incorporated 
molecules. Furthermore, the peptide nanoparticles, singly loaded or coloaded with boron-
dipyrromethene (BODIPY) and/or antisense oligonucleotides, were efficiently taken up by 
cells. Such amphiphilic peptides that led to noncytotoxic, reduction-responsive nanoparticles 
capable of codelivering hydrophobic and nucleic acid payloads simultaneously provide 
potential toward combined treatment strategies to exploit synergistic effects. 
3.2 Introduction 
Combined treatments are gaining increasing impact in medicine not only to exploit 
synergistic effects of therapeutics, but also to overcome multidrug resistance (MDR) in 
cancer therapies.204 This creates a tremendous demand for sophisticated carrier systems 
capable of codelivering therapeutics simultaneously for higher efficacy. For this purpose 
combinations of small drugs are beneficial, but drug/gene combinations are also of high 
interest, especially in the case of P-glycoprotein (P-gp) mediated MDR.204 Nanotechnology 
provides a vast array of opportunities and promise in the rational design of multifunctional 
drug delivery systems. Nanocarriers can be designed for the delivery of therapeutics: 
protecting them from being metabolized,63,64 enhancing bioavailability, lowering off-target 
effects, and decreasing the necessary drug dose by increasing accumulation at the diseased 
site.205 Of particular interest for P-gp mediated MDR is the codelivery of drugs and nucleic 
acids in a single nanocarrier system. Promising results were obtained by antisense 
oligonucleotide-mediated down-regulation of the overexpressed P-gp, responsible for drug 
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efflux, in combination with small molecule anticancer drugs.206,207 For incorporation of 
payloads, two main strategies are followed, where nucleic acids or drugs are either 
synthetically conjugated to the carrier or noncovalently condensed or entrapped.63,208 
Covalent strategies involve the linkage of polymers, proteins, peptides, and inorganic 
nanoparticles to nucleic acids or drugs,136 while noncovalent condensation is achieved via 
electrostatic interaction, hydrogen bonding, and hydrophobic interactions. Noncovalent 
nanocarriers for oligonucleotide delivery are usually able to cross cell membranes and deliver 
the cargo better than conjugated ones, but are in general more difficult to control.137,208 
Current strategies for codelivery of small molecule drugs and nucleic acids rely on lipids,209,210 
polymers,211,212 and conjugates,213,214 which form structures able to entrap small drugs as well 
as to noncovalently condense DNA or RNA. Further improvement of efficacy can be 
achieved by utilizing physiological microenvironments at pathological sites such as pH,72-75 
temperature,76 and redox potential77,78 as release triggers. Responsive polymeric systems and 
conjugates for codelivery were developed recently, bearing moieties sensitive to physiological 
triggers such as pH215-218 or redox potential.219-222 
Emerging peptide based self-assembled nanostructures in the field of nanomedicine are 
particularly interesting because they are considered to be inherently biocompatible and 
biodegradable.19,22,146 Specific inter- and intramolecular interactions between amino acids 
such as electrostatic interactions, hydrogen-bonding, hydrophobic interactions, and π–π-
stacking can be implemented to obtain highly ordered and defined assemblies. The bottom 
up rational design is based on selecting amino acids with the desired properties in order to 
create novel amphiphilic peptides able to self-assemble into defined architectures. 
Furthermore, the combination of distinct functionalities, such as responsiveness, can be 
implemented within one molecule enabling the development of peptides self-assembling into 
well-defined and multifunctional nanoparticles, which is a tremendous advantage due to 
simplicity and applicability for biomedical applications.145,223,224 Reported peptidic carriers for 
delivering a single drug comprise polyplexes,25,121,123 hydrogels,225 and micelles.122,144,145,224,226 
There are only a few peptidic codelivery systems described to date capable of delivering 
nucleic acids and small molecule drugs simultaneously.144,224,226 Recent reports describe 
peptides, consisting of a polyhistidine–polylysine hydrophilic peptide sequence coupled with 
a hydrophobic sequence comprising of alanine, phenylalanine, and/or leucine, which show 
synergistic cytotoxic effects when delivering p53 plasmid in combination with doxorubicin 
(Dox) or paclitaxel (PTX).144,226 Another report describes a slow release (20–30 h) of Dox 
from a polyhistidine–TAT conjugate at pH 5 compared to neutral pH accompanied by 
synergistic effects when codelivered with p53 plasmid.224 However, further improvement for 
stimuli responsiveness is essential to enhance a rapid delivery and/or release of coloaded 
payloads. 
Here, we aim for a straightforward rational design of new peptide nanoparticles that enhance 
the properties of the AcX3gT nanoparticles to favor codelivery and rapid release of small 
molecule drugs and nucleic acids simultaneously by reduction-responsiveness. The new 
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peptides are separated into three key structural features: the hydrophilic region (region 1), 
linker unit (region 2), and hydrophobic region (region 3) (Figure 21). The hydrophilic 
moiety was redesigned from the previous peptide AcX3gT by implementing nucleotide 
condensing sites, based on oligohistidine, known to promote these interactions.227 By 
introducing oligohistidine the slight surface charge is in addition intended to prevent 
aggregation, which limited AcX3gT potential use, when loaded with hydrophobic 
molecules.31 Moreover, using oligohistidine as the hydrophilic sequence preserves secondary 
aggregation to nanoparticles due to a pKa of 6.0 in contrast to previously reported 
nonacetylated K3gT, bearing lysines with a pKa of 10.7, which form micelles.30  
Increasing the number of aromatic side chains is expected to support molecule incorporation 
as already reported for AcX3gT. The nanoparticles were also expected to be smaller, thus 
more suitable for biomedical applications due to higher water solubility compared to 
AcX3gT.29,30 The stimuli-responsiveness to cellular redox potential was integrated to the 
sequence by using an artificial disulfide amino acid (region 2, Figure 21). By adding this 
linker in between the hydrophilic and hydrophobic sequences, we favor a higher release upon 
external stimuli, which was previously not available when designed only with peptide bonds. 
Therefore, in the structure of this new peptide, only the gramicidin-inspired seven-amino-
acid repeating unit gT remained from the previously reported peptide AcX3gT in order to 
maintain the previously observed self-assembly into nanoparticles that are capable of 
entrapping hydrophobic payloads. Characterization revealed that the three functional units 
enabled assembly of spherical peptide nanoparticles that were reduction sensitive (H3SSgT) 
and capable of loading desired model drug (boron-dipyrromethene (BODIPY)) and nucleic 
acid (antisense oligonucleotides (AON)) payloads simultaneously.  
	
Figure 21. Schematic representation of nanoparticle assembly incorporating AON and drugs. 
Designed amphiphilic peptide consists of three regions: hydrophilic (region 1), reducible linker 
(region 2), and hydrophobic (region 3). Amphiphilic peptide assembles in a first step into micelles, 
incorporating drug in the hydrophobic region and nucleotides along their hydrophilic region. Further 
self-assembly leads towards spherical nanoparticles, potentially multicompartment micelles.29 Adapted 
from Gunkel-Grabole et al.1 Reproduced by permission of The Royal Society of Chemistry. 
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We selected BODIPY as the model molecule with the appropriate hydrophobicity and 
molecular weight, while the hydrophilic DoxHCl served only to demonstrate the ability of 
the peptide nanoparticles to encapsulate hydrophilic molecules as well. Fluorescence 
correlation spectroscopy (FCS) analysis was used to evaluate whether the reduction 
responsive particles were able to rapidly release all payloads in a reducing environment. A 
final analysis in HeLa cells was performed to show that the reduction-sensitive H3SSgT 
peptide nanoparticles are taken up and the cargo retains its functionality. Although stimuli-
responsive codelivery architectures have been developed for polymer, lipid, and peptide-
conjugate self-assemblies our strategy has the advantage of providing purely peptidic and 
biodegradable nanoparticles for efficient codelivery and release of oligonucleotides and drugs 
simultaneously upon reduction. 
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3.3 Results and Discussion 
3.3.1 Design, Synthesis, and Characterization of Peptides and 
Their Self-Assemblies 
Two new amphiphilic peptides, H3gT and H3SSgT, were designed from the previously 
reported peptide, AcX3gT (Figure 22A). The first, H3gT, was designed with the cationic 
histidine amino acids in place of the acetylated lysines in order to improve the encapsulation 
of charged species such as AON into the self-assembled nanoparticles (Figure 22B). In order 
to improve the release of cargo molecules from H3gT nanoparticles, a second peptide 
H3SSgT was designed by incorporating an artificial disulfide amino acid to serve as a 
reduction cleavable linker (Figure 22C). 
	
Figure 22. Synthesized peptide sequences of AcX3gT (A),31 H3gT (B), and H3SSgT (C). The 
hydrophobic gT sequence is orange, the hydrophilic sequence is green, and the reducible S–S linker is 
blue. TEM micrographs represent self-assembled structures of each peptide. Scale bar: 200 nm. 
Inserting the linker between the hydrophilic oligohistidine and hydrophobic gT will lead to 
separation of the charged interactions of the oligohistidine and the hydrophobic interaction 
by the gT, leading to dissolution of the nanoparticle and release of the encapsulated 
molecules. The amphiphilic peptides AcX3gT, H3gT, and H3SSgT were synthesized using 
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conventional solid phase peptide synthesis (SPPS) and purified by high-performance liquid 
chromatography (HPLC). The peptide masses of AcX3gT, H3gT, and H3SSgT were 
measured by liquid chromatography electron spray ionization mass spectrometry (LC-ESI-
MS) to match the expected values of 1653.9 g/mol, 1512.8 g/mol, and 1746.8 g/mol, 
respectively (Figure 23A–C). 
	
Figure 23. HPLC chromatogram (detection of tryptophan at 280 nm) and LC-ESI-MS data of 
purified AcX3gT (A), H3gT (B), and H3SSgT before (C) and after (D) treatment with DTT. 
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Similar to AcX3gT, both H3gT and H3SSgT self-assembled in water leading to spherical 
nanoparticles. The change in the sequence from acetylated lysines of AcX3gT to 
oligohistidine of H3gT or H3SSgT did not affect the assembly properties of the amphiphilic 
peptides, revealing spherical shapes and a smooth surface by transmission electron 
microscopy (TEM) (Figure 22). However, the initial concentration of each peptide led to 
differences in nanoparticle size. There is a linear relation between initial concentration and 
nanoparticle size for AcX3gT, with a lower plateau at 260 nm for concentrations below 0.5 
mg/mL.30 In contrast, H3gT and H3SSgT exhibited sizes of about 150 nm and 100 nm, 
respectively, for nanoparticles assembled from peptide concentrations of 0.2 mg/mL. This is 
regarded as optimal size for drug delivery systems to have sufficient loading but still avoid 
excessive clearance by macrophages.67,68 Replacing the acetylated lysines of AcX3gT with 
histidines of H3gT did not alter the ability to form spherical nanoparticles in contrast to 
nonacetylated analogs of AcX3gT (K3gT).30 This can be attributed to a closer proximity 
between the side chain functional groups and its aromatic nature, which enables π–π-
stacking, cation–π interactions, and hydrogen–π interactions.228 
3.3.2 Encapsulation of Payload and Characterization of Loaded 
Nanoparticles 
The ability of the new peptides H3gT and H3SSgT to embed payloads was compared to 
AcX3gT using a hydrophobic small drug molecule model (BODIPY), or Atto550 labeled 
antisense oligonucleotides (AON). First, fluorescence correlation spectroscopy (FCS), 
which distinguishes fluorescent species diffusing free in solution compared to those 
associated with nanoparticles, was measured to ensure the new peptides maintained the 
ability to load hydrophobic payloads. Varying the peptide sequence to include histidines or a 
reduction sensitive linker did not affect the incorporation of the hydrophobic molecule 
BODIPY (Table 3). AcX3gT and H3SSgT showed high loading efficiencies; however, upon 
encapsulating BODIPY in H3gT nanoparticles, the particles quickly shifted to large 
aggregates, which cannot be measured by FCS. The ratio of loaded cargo was obtained by 
fitting the autocorrelation functions using two component fits: free dye and dye-loaded 
peptide nanoparticles (Table 3). Next, AONs were loaded into each peptide nanoparticle. By 
FCS, AcX3gT showed a correlation curve identical to that of the free AON (Figure 24A). 
This indicated that AcX3gT was incapable of binding AON due to a lack of charge 
interactions. However, both the H3gT and H3SSgT, which contain the oligohistidine 
sequence, were able to bind AON showing an increased diffusion time compared to free 
AON alone (Figure 24A, Table 3).  
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Table 3. FCS Characterization of Singly and Coloaded Peptide Nanoparticles.a  
peptide 
nanoparticles 
payload diffusion time 
(µs) 
hydrodynamic  
diameter (nm) 
loading efficiencyb 
(%) 
Free species 
BODIPY 61 ± 2.8 N/A N/A 
AON 102 ± 7.3 N/A N/A 
AcX3gT 
BODIPY 7700 ± 439 174 ± 10 82 ± 7 
AON N/A N/A N/A 
H3gT 
BODIPY N/A N/A N/A 
AON 8430 ± 2400 235 ± 67 89 ± 3 
H3SSgT 
BODIPY 4550 ± 330 103 ± 8 93 ± 6 
AON 5640 ± 390 157 ± 11 99 ± 1 
Coloaded 
H3SSgT 
BODIPY 4270 ± 756 96 ±17 91 ± 2 
AON 3226 ± 636 90 ± 18 90 ± 3 
aData represents average ± SD (n = 3). 
bTwo component model fit of the autocorrelation function. 
In contrast, the effective drug embedding efficiency of DoxHCl (as a hydrophilic small 
molecule drug) to H3gT and H3SSgT was determined to be 1.5 and 2.3 mg/g by 
fluorescence emission. The low embedding efficiencies resulted from the hydrophilicity of 
DoxHCl, thus lacking entropic driving forces in contrast to hydrophobic payloads. Due to 
the inability of AcX3gT to bind AON and the formation of large nanoparticles when H3gT 
encapsulates BODIPY, we will further focus on H3SSgT with the other two peptides being 
analyzed for comparison when appropriate. 
The successful incorporation of BODIPY and AON into H3SSgT nanoparticles was 
confirmed by confocal laser scanning microscopy (CLSM) (Figure 24F,G). Even the low 
DoxHCl loading was confirmed by CLSM micrographs (Figure 24H). The size and 
morphology of the nanoparticles were measured by dynamic light scattering (DLS) and 
scanning electron microscopy (SEM), respectively (Figure 24B–E) and was confirmed by 
atomic force microscopy (AFM) for DoxHCl-loaded H3SSgT particles (Figure 35 
(Supporting Information)). For AON- and DoxHCl-loaded particles only marginal 
differences in size and morphology were detected revealing smooth surfaces by SEM and 
diameters of 135 ± 22 nm and 165 ± 40 nm, respectively. In DLS similar diameters have been 
obtained (148 and 187 nm, respectively; Figure 24, Table 4), the differences being related to 
the drying effect in SEM measurements. Particles loaded with BODIPY preserved the size as 
AON-loaded nanoparticles (149 nm; Figure 24, Table 4), but smaller diameters and rougher 
surfaces were observed by SEM, compared to nonloaded H3SSgT nanoparticles (Figure 34 
(Supporting Information), Table 4).  
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Figure 24. FCS autocorrelation curves (A) comparing free AON (dots) and AON complexed with 
AcX3gT (solid line), H3gT (broken line), and H3SSgT (dashes) nanoparticles. DLS data (B) for 
H3SSgT particles loaded with BODIPY (red), AON (green), and DoxHCl (blue). SEM and CLSM 
micrographs of H3SSgT nanoparticles loaded with BODIPY (C,F), AON (D,G), and DoxHCl (E,H). 
Scale bars for SEM micrographs are 500 nm (C–E), and 10 µm for CLSM micrographs (F–H).  
 
Table 4. Hydrodynamic Diameters and PDIs from DLS Measurements of H3SSgT 
Nanoparticles Loaded with BODIPY, AON, and DoxHCl. 
peptide nanoparticles 
hydrodynamic 
diameter (nm) PDI 
H3SSgT-BODIPY 149 0.23 
H3SSgT-AON 148 0.20 
H3SSgT-DoxHCl 187 0.24 
H3SSgT 218 0.37 
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The difference in morphology of BODIPY-loaded particles can be attributed to hydrophobic 
interactions of BODIPY with the hydrophobic gT sequence of the peptide and the formation 
of intermolecular π–π-stacking between BODIPY and tryptophan229 interfering with the self-
assembly process. The smaller sizes for AON-loaded compared to nonloaded particles can be 
attributed to the charge interaction resulting in more compact assemblies. Further analysis of 
the AON-loaded nanoparticles was also performed using energy dispersive X-ray 
spectroscopy (EDX) to identify the simultaneous presence of the sulfur in the linker and the 
phosphorus of the AON backbone. Indeed, both elements were detected in AON-loaded 
nanoparticles while no phosphorus signal was observed for particles loaded with BODIPY 
(Figure 25B,C). Also, zeta potential analysis showed an optimal DNA to peptide ratio at 
40 µg AON/mg peptide where the surface charge approached from cationic, known to 
promote cell uptake,230 toward neutral, known to decrease protein interactions and clearance 
(Figure 25A).231  
	
Figure 25. Zeta potential of various AON to H3SSgT peptide ratios (A). Energy-dispersive X-ray 
(EDX) spectrum of AON-loaded H3SSgT peptide nanoparticles (B). EDX spectrum of BODIPY-
loaded H3SSgT nanoparticles (C). 
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3.3.3 Stimuli-Responsive Disintegration of Peptide Nanoparticles 
and Release of Payload 
The implementation of a disulfide linker should allow H3SSgT nanoparticles to efficiently 
release loaded cargo molecules when exposed to physiological concentrations (10 mM) of 
dithiothreitol (DTT) through reductive cleavage of the hydrophilic from the hydrophobic 
sequence. LC-ESI-MS was used to detect the decomposition of H3SSgT peptide before and 
after addition of reducing agent, corresponding to the full length peptide ([M+2H]2+: 
m/z 874.3; [M+3H]3+: m/z 583.2) (Figure 23C) and the cleaved hydrophobic S–gT 
([M+H]+: m/z 1260.7; [M+2H]2+: m/z 630.8) (Figure 23D). The detection of the H3–S 
sequence was not found due to it having a drastically lower molar absorption at 280 nm 
compared to the tryptophans on the gT sequence and it being hidden in the baseline. Next, 
H3SSgT nanoparticles were investigated using TEM and SEM to visualize if the cleavage of 
the peptide led to subsequent destruction of the nanoparticles. After addition of DTT the 
micrographs showed decomposition of the spherical nanoparticles compared to H3SSgT 
nanoparticles without DTT (Figure 26). The smaller particles represent partly decomposed 
peptide nanoparticles due to the disintegration of the particles. The population with larger 
diameters suggests the aggregation of the cleaved hydrophobic gT sequence due to their 
instability in aqueous solution (Figure 26B). TEM micrographs indicate the coexistence of 
various stages of decomposition, from intact peptide nanoparticles up to aggregates. AcX3gT 
and H3gT did not show particle decomposition when treated with DTT (Figure 27).	
	
Figure 26. TEM (top) and SEM (bottom) micrographs of responsive H3SSgT nanoparticles before 
(A) and after treatment with DTT (B). Scale bars: 200 nm. 
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Figure 27. SEM micrographs of AcX3gT before (A) and after (B) DTT treatment, and H3gT before 
(C) and after (D) DTT treatment. Scale bars: 200 nm. 
FCS was then used to assess the release of payload during particle decomposition. We 
selected BODIPY to be codelivered with AON because it is appropriate as a model molecule 
in terms of hydrophobicity and molecular weight, as well as being easily detected by FCS. 
Due to the incompatibility of DoxHCl with FCS detection, it was not feasible to use this 
small molecule drug for these release assays. 10 mM DTT was added to H3SSgT 
nanoparticles loaded with BODIPY or AON. Nanoparticles loaded with AON showed a fast 
release profile reaching approximately 50% after 15 min, while with BODIPY 50% release 
was not achieved until 30 min (Figure 28). Fast release under reductive conditions while 
maintaining payloads, when incubated in buffer differentiates our system from slowly 
releasing, pH-sensitive peptide nanoparticles showing a pH 5/pH 7.4-release ratio of 2.224 
Similarly, our system is faster than amphiphilic peptides passively releasing hydrophobic 
payload from gene/drug coloaded particles to 35% after 18 h,144 or 40% after 60 h.226 Both 
BODIPY- and AON-loaded nanoparticles showed almost complete disintegration by 120 
minutes in the presence of DTT, with no release occurring without DTT (Figure 28). 
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Figure 28. Release curves of BODIPY (A) or AON (B) loaded nanoparticles: squares represent 
H3SSgT+DTT, circles are H3SSgT–DTT, triangles are AcX3gT+DTT, and diamonds represent 
H3gT+DTT. Green and red lines are exponential fits of the H3SSgT data points using the Levenberg–
Marquardt algorithm. Data represents average ± SD (n=3). 
The slightly higher release rate of AON can be associated with their hydrophilicity, 
positioning them on the outer hydrophilic corona of the individual micelles, whereas the 
hydrophobic payload is trapped in the micelle core, shielded by the hydrophilic sequence of 
the peptide. The release from H3SSgT in the presence of DTT was then compared with 
AcX3gT, for BODIPY-loaded nanoparticles, or H3gT, for AON-loaded nanoparticles. 
AcX3gT and H3gT, treated with DTT, did not result in an increased population of freely 
diffusing payload indicating no release (Figure 28). 
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3.3.4 Coloading and Combined Release from H3SSgT 
Nanoparticles 
To assess the suitability of the stimuli-responsive H3SSgT nanoparticles to serve as 
multifunctional codelivery carriers they were coloaded with both AON and BODIPY. The 
coloaded peptide nanoparticles were analyzed with CLSM to evaluate the simultaneous 
existence of both payloads in the particles (Figure 29A–C). An intensity profile through the 
micrograph indicated that not all particles are loaded equally (Figure 29D), but most of the 
particles contained both AON and BODIPY. 
	
Figure 29. CLSM micrographs of AON- (A, red channel) and BODIPY- (B, green channel) coloaded 
H3SSgT nanoparticles (C, merged). Fluorescence intensity profile of a cross section of micrograph C 
(D). FCS release curve of BODIPY and AON from H3SSgT coloaded nanoparticles (E). Data 
represent average ± SD (n=3). 
This observation is consistent with a colocalization analysis of an overlay image, revealing 
mostly colocalized fluorescence signals (Figure 30). The Mander coefficient was calculated 
to 0.844, where 1 represents perfect colocalization and 0 represents no colocalization.232 
Fluorescence cross-correlation spectroscopy (FCCS) was used to quantify the fraction of 
coloaded nanoparticles. FCCS is a dual-color variant of the FCS technique for the 
colocalization of two different fluorophores by cross-correlation of the individual channels.233  
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Figure 30. Colocalization analysis (A) and CLSM picture (B) of AON/BODIPY coloaded peptide 
nanoparticles. The fluorescence information was transformed to single channel 8-bit pictures. The 
Mander coefficient was calculated to 0.844 using the Mander coefficient plugin in ImageJ with CH1 
corresponding to AON (red channel) and CH2 corresponding to BODIPY (green channel). 
All data were normalized with the free cargo mixture equaling 0% cross-correlation and a 
standard double-labeled DNA equaling 100% cross-correlation. It resulted in a calculated 
complete coloading of the particles (Figure 31). To evaluate, if the responsiveness was 
influenced by coloading, corelease of both BODIPY and AON was compared by FCS to 
singly loaded nanoparticles. 50% of BODIPY was released faster from coloaded nanoparticles 
at around 10 min (Figure 29E) compared to singly loaded ones (≈ 30 min) (Figure 28A). 
This could be attributed to the additional interaction of both cargoes with the peptide, 
affecting the hydrophilic and hydrophobic interactions and potentially disturbing the 
assembly leading to less density within the nanoparticles, in contrast to peptide nanoparticles 
bearing only one type of guest molecules (Figure 28). The AON release behavior is almost 
congruent with singly loaded analogues due to different binding mode to the carrier.  
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Figure 31. Correlation functions and fits of double labeled DNA (A), free payloads (B), and coloaded 
H3SSgT peptide nanoparticles (C). Cross-correlation (red), BODIPY (blue), and AON (green). 
Degree of coloading with respect to all BODIPY-loaded particles is given by θ=cx/ctotal, BODIPY=(G0,x–
1)/(G0,AON–1), where G is the autocorrelation amplitude.233 
3.3.5 Cell Uptake and Anti-Proliferation Activity 
The reduction sensitive H3SSgT nanoparticles were evaluated for cytotoxicity to ensure the 
particles do not rapidly cause cell death. Peptide nanoparticles were nontoxic for 
concentration up to 1000 µg/mL at incubation times of 24 and 48 h (Figure 36A 
(Supporting Information)). Also, when the nanoparticles were treated with DTT prior to 
viability experiments the fragments did not show any toxicity after 48 h incubation (Figure 
36C (Supporting Information)). Cell toxicity for the free peptides could not be achieved due 
to the spontaneous self-assembly in aqueous media. Cell uptake and intracellular behavior in 
HeLa cells were investigated with H3SSgT nanoparticles loaded with BODIPY or AON or 
coloaded with both BODIPY and AON. Qualitative analysis of the cells by CLSM showed 
increased uptake for singly loaded (Figure 37–38 (Supporting Information)) and coloaded 
peptide nanoparticles with BODIPY (Figure 32A) and AON (Figure 32C). Cellular uptake 
was additionally demonstrated to be comparable for coloaded particles when initially 
incubated in serum-containing medium (Figure 33). The increased uptake to cells was 
subsequently quantified by fluorescence-assisted cell sorting (FACS) analysis. This resulted 
in a 10-fold higher uptake of embedded AONs compared to free AONs when equivalent 
AON concentrations were applied to the cells (Figure 32E).  
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Figure 32. CLSM micrographs of coloaded H3SSgT peptide nanoparticle accumulation in HeLa cells 
with BODIPY channel (A), Hoechst nucleus stain (B), AON channel (C), and merged (D). FACS 
data of cell uptake for AON-loaded particles obtained from mean fluorescence intensities (E). Cell 
growth inhibition studies of free DoxHCl (solid line), or DoxHCl-loaded H3gT (broken line) and 
H3SSgT (dashed line) peptide nanoparticles (F). Data represents average ± SD (n = 3). 
Free cargo as well as a mixture of BODIPY and AON (to ensure no cross interaction of 
molecules leading to uptake) did not show any detectable uptake (Figure 37–39 (Supporting 
Information)). This was expected for the negatively charged AON because it is commonly 
known that large anionic molecules do not internalize into cells. Free BODIPY is often 
shown to enter the cell; however, the amount of free BODIPY was the same as that in the 
particle solutions. At such low concentrations, free BODIPY was not enough to be seen by 
CLSM whereas when colocalized into peptide nanoparticles and more readily taken up due 
to the positive surface charge, higher signals have been observed.  
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Figure 33. CLSM micrographs of coloaded nanoparticles with (1) and without (2) FBS. AON (a), 
Hoechst 33342 cell nuclei stain (b), BODIPY (c), and merge (d). 
For subsequent cell growth inhibition studies only the H3gT and H3SSgT particles were 
loaded with hydrophilic DoxHCl to demonstrate the cell uptake and delivery qualities as well 
as the protection of the drug for more effectiveness. To assess the applicability of stimuli-
responsive peptide nanoparticles as drug delivery system, DoxHCl was loaded into H3SSgT 
nanoparticles and applied to HeLa cells. The IC50 value of DoxHCl-loaded peptide 
nanoparticles was determined for H3SSgT compared to free DoxHCl (Figure 32F). The 
IC50 of DoxHCl-loaded H3SSgT peptide nanoparticles (H3SSgT) was found to be 150 nM, 
approximately four times lower than for free DoxHCl (530 nM). The decrease of IC50 is due 
to the hydrophilic character of DoxHCl, which has limited cell permeability compared to the 
nanoparticles. The decrease of IC50 value compared to free DoxHCl in HeLa cells is indirect 
proof of DoxHCl release from nanoparticles upon uptake, and supports our system as a good 
candidate for codelivery of small molecular weight molecules and AON. In addition, as the 
peptide fragments did not show any toxicity after 48 h incubation (Figure 36C (Supporting 
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Information)), we consider that the lower IC50 of DoxHCl-loaded H3SSgT nanoparticles 
than DoxHCl-loaded H3gT nanoparticles is the results of better DoxHCl release from 
H3SSgT nanoparticles due to the S–S breakage. 
Also, when compared to the nonreducible DoxHCl-loaded H3gT nanoparticles (280 nM), 
H3SSgT had an IC50 about two times lower. This difference demonstrates the influence of 
the added stimuli-responsive linker. H3gT nanoparticles are taken up by cells similarly to 
H3SSgT but do not rapidly or efficiently release the DoxHCl, which is why the IC50 remains 
higher. The stimuli-responsive H3SSgT particles reveal, in addition to a similar uptake 
performance compared to H3gT, a potent release mechanism allowing the drug to achieve its 
full potential. 
3.4 Conclusion 
Development of nontoxic, biocompatible, and biodegradable nanocarriers for codelivery and 
stimuli-responsive release of oligonucleotides and small drugs remains a remarkable 
challenge. We designed and synthesized responsive amphiphilic peptides, which assemble 
into peptide nanoparticles that were engineered to condense oligonucleotides via 
electrostatic interactions with histidine and to incorporate small molecules within their 
multicompartment micellar structure. The nanoparticles are able to carry hydrophobic and 
hydrophilic payloads as well as oligonucleotides, which can be released upon a physiological 
trigger. In addition, the histidines in the primary sequence will support uptake to cells and 
subsequent proton sponge effect accelerating endosomal escape by its buffering capacity. 
Unlike most reported codelivery systems, our stimuli-responsive nanoparticles are purely 
peptidic in nature and therefore intrinsically biodegradable. In contrast to the previously 
reported peptidic codelivery system based on Fmoc-lysine-histidine constructs revealing 
sizes of up to 550 nm,224 the diameters of the present nanoparticles match desired values for 
intravenous application. Furthermore, the implemented release mechanism is highly 
sensitive to a reduction potential in the cytosol to release coloaded payloads with great 
efficiency. All of these characteristics make our peptide nanoparticles a promising candidate 
for codelivery of multiple therapeutic payloads including hydrophobic Dox and plasmid 
DNA. Therefore, ongoing optimization experiments exploring the biocompatibility of these 
nanoparticles, their stability in animal blood serum, and in vivo biodistribution and 
pharmacokinetic studies are planned to improve this system into a functional delivery system 
with high therapeutic effects.  
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3.5 Supporting Information 
3.5.1 Further Characterization of Nonloaded and Loaded 
Nanoparticles 
	
Figure 34. DLS of nonloaded H3SSgT peptide nanoparticles (A). SEM micrograph of nonloaded 
H3SSgT nanoparticles (B). Scale bar: 200 nm. 
	
Figure 35. AFM profiles of DoxHCl-loaded H3SSgT peptide nanoparticles. 
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3.5.2 Toxicity Studies 
	
Figure 36. MTS cell viabilities of HeLa cells treated with H3SSgT nanoparticles for 24 and 48 h (A) 
and H3gT nanoparticles for 24 h (B). MTS viability of DTT treated H3SSgT (C). Values represent 
average ± SD (n=5 (A/C), n=3 (B)). 
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3.5.3 Cell Uptake of Singly Loaded Nanoparticles and Free 
Payloads 
	
Figure 37. LSM micrographs of AON-loaded particle uptake to HeLa cells (1). Free AON on HeLa 
cells (2). Hoechst 33342 cell nuclei stain (a), transmission (b), AON (c), and merge (d). 
	
Figure 38. LSM micrographs of BODIPY-loaded particle uptake to HeLa cells (1). Free BODIPY on 
HeLa cells (2). Hoechst 33342 cell nuclei stain (a), BODIPY (b), transmission (c), and merge (d). 
	
Severin J. Sigg 
60 
	
Figure 39. CLSM micrographs of HeLa cells incubated with a mixture of AON and BODIPY. AON 
(A), Hoechst 33342 cell nuclei stain (B), BODIPY (C), transmission (D), and merge (E). 
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Chapter 4 
4 Polylysine- and Polyhistidine-Based 
Amphiphilic Peptides for Plasmid DNA 
Transfection 
The following chapter describes the development of transfection agents for plasmid 
DNA delivery self-assembled from amphiphilic peptides. Various peptide architectures, 
comprising different lengths of hydrophobic sequences, derived from gramicidin A, in 
conjunction with polyhistidine or polylysine are examined and discussed on their 
transfection performance and toxicity to mammalian cells. 
 
 
	
Figure 40. Polylysine- and polyhistidine-based amphiphilic peptides condensing and delivering 
plasmid DNA to the cell nucleus inducing production of mRNA encoding for green fluorescent 
protein. 	
Severin J. Sigg 
62 
4.1 Abstract 
In this study, amphiphilic peptides comprised of polylysine or polyhistidine in conjunction 
with hydrophobic sequences derived from gramicidin A are described and synthesized to 
study the effect of the lysine block length and the differences between polyhistidine and 
polylysine regarding gene delivery. The peptides were synthesized by standard Fmoc-based 
solid phase peptide synthesis. Peptide nanoparticles were formed by first condensing plasmid 
DNA (pDNA) at various nitrogen-to-phosphorus ratios (N/P-ratios) followed by self-
assembly. pDNA-loaded constructs were thoroughly characterized and examined on their in 
vitro transfection performance using U87 cells. First, H3SSgT, introduced in chapter three, 
capable of codelivering and -releasing antisense oligonucleotides (AON) and small molecule 
drugs in a reduction-responsive manner was examined on its suitability for delivering pDNA. 
The N/P-ratios were optimized to 10 according to electrophoretic mobility shift assays 
(EMSA) and zeta-potential measurements. Incubation with reducing agent led to partial 
release of the incorporated pDNA. Secondly, the newly introduced polylysine peptides 
AcK6gA and K10gA were examined on their pDNA condensing and particle formation 
abilities. They revealed high pDNA-loading capability and formed nanoparticles similar in 
shape and size compared to pDNA-loaded H3SSgT nanoparticles. AcK6gA and K10gA 
nanoparticles achieved transfection efficacies at levels of the gold standard Lipofectamine 
(~60 %) while H3SSgT nanoparticles revealed a fourfold lower efficiency (15 %). Increased 
surface charge induced enhanced transfection efficiencies; however, it also led to elevated 
cytotoxicity, which is frequently observed for polycationic transfection agents. Intense GFP 
fluorescence of transfected U87 cells demonstrated functionality of the rationally designed 
amphiphilic peptides and suggests further optimization of the presented system to achieve a 
nontoxic highly efficient gene transfection agent.  
4.2 Introduction 
In the past decades, nonviral gene therapy gained considerable attention, due to a much 
better safety profile compared to viral gene delivery vectors.234 A vast array of transfection 
agents have been developed based on polycations such as poly-L-lysine,235-237 
poly(ethyleneimine) (PEI),238-240 and polyamidoamine (PAMAM).241,242 However, the 
resulting polyplexes usually exhibit an excess quantum of positive charge, interacting with cell 
membranes and inducing lethal cytotoxicity, which remains a major challenge.79,80,243-246 To 
overcome this drawback, polycations were conjugated to molecules with various 
physicochemical properties to promote nanoparticle formation driven by entropic forces. 
Numerous architectures of lipids, polymers, and peptides have been investigated on their 
capability of delivering nucleic acids (Chapter 1). In this chapter, we will focus on lysine- and 
histidine-rich molecular designs to achieve this goal via well-defined monodisperse peptide 
  Chapter 4 
  63 
sequences. While polylysine has exceptional nucleic acid condensing capabilities, 
polyhistidine has the additional feature of supporting the proton sponge effect and therefore, 
accelerating endosomal escape of the nanoparticles to the cytosol, which is essential for an 
effective treatment.247 
Studies have shown that relatively short and defined polylysine sequences, conjugated to 
hydrophobic moieties are promising noncytotoxic transfection carriers. Pentalysine peptides 
were reported to have moderate nontoxic transfection capabilities when coupled to different 
lengths of hydrophobic peptide sequences.248 Histidine–lysine peptides exhibit also great 
promise in noncytotoxic gene delivery. Various nonapeptides comprising histidines and 
lysines conjugated to PEI demonstrated increased gene transfection efficiency compared to 
bare PEI, thereby highlighting the positive transfection effect mediated by these peptides.249 
Also, polylysine–Tat constructs250 and disulfide-linked histidine–arginine peptides251 
revealed promising transfection performances. Although, polylysine has been reported to be 
cytotoxic at certain conditions,252 other studies have also shown nontoxicity and 
immunocompatibility of these peptides.253  
Herein, we describe the design and synthesis of amphiphilic peptides comprising polylysine 
and hydrophobic sequences inspired form gramicidin A (gA). The sequences are constructed 
to interact with plasmid DNA via electrostatic interaction. Nanoparticles are formed by self-
assembly of the amphiphilic molecules. The polylysine sequences were designed to contain a 
glycine spacer after every third amino acid, providing better flexibility of the peptides to 
arrange along the pDNA. The transfection efficiency was investigated using pDNA encoding 
for green fluorescent protein (GFP) and compared to previously introduced H3SSgT. 
Similarly, the cytotoxicity was evaluated using different methods. 
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4.3 Results and Discussion 
4.3.1 Synthesis and Characterization of Peptides 
In this study, AcK6gA and K10gA were examined on their capability to form nanoparticles 
with pDNA and compared to previously reported H3SSgT (Chapter 3). All peptides were 
synthesized on Rink amide resin using standard Fmoc solid phase peptide synthesis (SPPS) 
technique and purified via high performance liquid chromatography (HPLC). The 
hydrophilic regions of the newly introduced peptides consist of different lengths of polylysine 
separated by glycine after every third lysine to provide flexibility along the backbone, 
potentially increasing plasmid DNA condensing capabilities (Table 5). AcK6gA and K10gA 
bear hydrophobic sequences derived from gramicidin A (gA) while H3SSgT is equipped 
with a hydrophobic region comprised of gT, a truncated version of gA. AcK6gA was 
previously reported to form multilamellar structures when mixed with the oppositely charged 
glutamic acid analogue,28 H3SSgT was described to form nanoparticles with sizes around 
100–200 nm (Chapter 3). The codes and sequences of the peptides as well as the chemical 
composition of the linker-unit are listed in Table 5. Lysines and histidines are known to 
condense pDNA efficiently.227,254 Furthermore, histidines or combinations of lysines and 
histidines promote cell uptake and have a positive effect on transfection efficiency.254-257 The 
number of charges per molecule, chemical nature, and resulting cooperative effects of carrier 
molecules are crucial factors for pDNA binding and condensing abilities, which also affect 
cell uptake and transfection performance.258,259  
Table 5. Codes, Sequences, and Chemical Structure of Amphiphilic Peptides and Reducible 
Linker, Including Molecular Masses. 
code/name sequence/chemical structure 
mass           
(g mol-1) 
Z -NH-(CH2)2-S–S-(CH2)2-NH-CO-(CH2)2-CO-  
-gA  -V-G-A-DL-A-DV-V-DV-[W-DL]3-W-CONH2 1711.1 
-gT  -[W-DL]3-W-CONH2 1100.3 
H3SSgT  H2N-H3-Z-[W-DL]3-W-CONH2 1746.8 
AcK6gA  Ac-K3-G-K3-V-G-A-DL-A-DV-V-DV-[W-DL]3-W-CONH2 2678.3 
K10gA  H2N-K-[G-K3]3-V-G-A-DL-A-DV-V-DV-[W-DL]3-W-CONH2 3263.1 
 
4.3.2 Plasmid DNA Condensation and Nanoparticle Formation 
The synthesized peptides AcK6gA, K10gA, and H3SSgT were used to form nanoparticles 
with pDNA via electrostatic interaction and subsequent self-assembly driven by the 
amphiphilic character of the peptides. The hydrophilic sequences were synthesized to 
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different lengths of polylysine (hexalysine and decalysine) or polyhistidine. Both amino acids 
differ in their pKa. While lysine has a pKa of 10.7 for the ε-amino group, histidine exhibits a 
pKa of 6.0 for the imidazole nitrogen. Plasmid DNA encoding for GFP was condensed within 
peptide nanoparticles at different N/P-ratios.  
	
Figure 41. EMSA (1.2 % agarose gel) and zeta potential of pDNA-loaded AcK6gA and K10gA 
nanoparticles. pDNA-loaded AcK6gA nanoparticles at N/P-ratios of 0.5, 1, 2, 5, and 10 (A); pDNA-
loaded K10gA nanoparticles at N/P-ratios of 0.5, 1, 2, 5, and 10 (B); zeta potential of pDNA-loaded 
AcK6gA and K10gA nanoparticles at N/P-ratios of 1, 2, and 10 (C). 
In order to optimize the N/P-ratio of each individual peptide the binding abilities were 
determined by electrophoretic mobility shift assays (EMSA) using 1.2 % (w/v) agarose gels 
and zeta potential measurements. EMSA indicated a shift from partially bound pDNA at an 
N/P-ratio of 1 to fully condensed pDNA at an N/P-ratio of 5 for AcK6gA (Figure 41A). 
K10gA revealed complete condensation of pDNA at an N/P-ratio of 2 (Figure 41B), slightly 
lower compared to AcK6gA. This could be attributed to a cooperative binding effect. K10gA 
reveals a higher number of charges per molecule, which cooperatively supports overall 
condensation of pDNA, compared to AcK6gA. However, zeta potential measurements 
revealed rather similar values for both peptides, changing to positive surface charges above an 
N/P-ratio of 2 (Figure 41C). The required N/P-ratios for a complete pDNA condensation 
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are in the range of other reported peptide-based systems.260,261 These indicate very effective 
pDNA-binding of the peptides via electrostatic interaction. It allows for the formation of 
moderately positively charged constructs presumably avoiding toxic effects emerging from 
interaction of positive charges with the phospholipid bilayer of cell membranes. The 
amphiphilic peptides probably arrange along the pDNA by electrostatic interaction and 
assemble subsequently to spherical nanoparticles through intermolecular hydrophobic 
interaction of the gA-sequence.  
	
Figure 42. Zeta potentials and EMSA of H3SSgT-pDNA nanoparticles. Zeta-potentials (A), and 
EMSA (B) of GFP-encoding pDNA loaded H3SSgT nanoparticles using different N/P-ratios ranging 
from 2 to 50. 
EMSA of H3SSgT, bearing a polyhistidine as pDNA condensing sequence revealed complete 
binding at an N/P-ratio of 10 (Figure 42A). However, the investigated values for N/P-ratios 
from 2 to 50 do not allow conclusive statements and comparisons to the former constructs 
built from AcK6gA and K10gA. Zeta potentials of pDNA-loaded H3SSgT nanoparticles were 
positive above N/P-ratios of 10 (Figure 42B), but comparably moderate in respect of the 
polylysine peptide nanoparticles (AcK6gA and K10gA). A slightly positive surface charge is 
known to support cell uptake and can lead to better efficiency;230,246,262 however, higher 
surface charge density can also lead to protein corona formation and clearance231 and toxic 
effects.243-245 Moreover, noncharged particles tend to aggregate while charged analogs reveal 
repulsive interactions avoiding aggregation behavior. Thus, for further studies the 
nanoparticles were assembled using the lowest N/P-ratio to still obtain slightly positive zeta 
potential values.  
TEM was used to assess the morphology and size of the nanoparticles, revealing spherical 
shapes and diameters of 45 ± 10 nm for AcK6gA (N/P=5.5), 53 ± 13 nm for K10gA 
(N/P=10), and 60 ± 13 nm for H3SSgT (N/P=20) (Figure 43). The sizes are at the lower 
limit of the optimal range for drug/gene delivery carriers, which is generally regarded to be 
around 100–200 nm, also depending on shape, surface chemistry, and specific target cells.263 
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However, CALAA-01 for instance was reported to reveal the best efficacy at diameters of 
around 50 nm, therefore the obtained values lay in a promising range for being 
therapeutically active.264  
	
Figure 43. Representative TEM micrographs of pDNA-loaded peptide nanoparticles. pDNA-loaded 
AcK6gA (N/P=5.5) (A), K10gA (N/P=10) (B), and H3SSgT nanoparticles (N/P=20) (C). Scale 
bars: 200 nm. 
4.3.3 Reduction Triggered Release of pDNA From H3SSgT 
Nanoparticles 
Only H3SSgT among the other peptides in the present study carries a responsive linker as 
described in more detail in Chapter 3. The triggered release of pDNA in vitro was therefore 
only studied for this peptide. In contrast to codelivery of AON and small molecules, the 
peptide nanoparticles were assessed on their capability to carry and release larger nucleic 
acids (pDNA). pDNA was condensed within H3SSgT nanoparticles at N/P-ratios of 10 and 
20 due to previously determined slightly positive surface charge, which is considered to 
promote cell uptake while preventing protein corona formation.230,231 Reductive release of 
pDNA was subsequently assessed by EMSA after addition of reducing agent (DTT) (Figure 
44A). Release of pDNA was observed for H3SSgT nanoparticles when incubated with DTT 
while nontreated nanoparticles revealed no band for noncondensed pDNA. However, a fair 
amount of pDNA is still condensed within the nanoparticles indicated by nonmigrated bands 
in the agarose gel (Figure 44B). pDNA release form H3SSgT nanoparticles with N/P-ratios 
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of 10 and 20 was monitored for 6 h. Faster release was observed at lower N/P of 10 
compared to self-assemblies with an N/P of 20. Qualitative analysis of the gels revealed 
considerably slow release in contrast to previously reported AON-release profiles (Figure 
44C). It can be attributed to the significantly larger size of the pDNA in contrast to AON, 
which possibly results in more entanglement and less defined assembly architecture. This 
could additionally alter the accessibility of the reduction responsive linker units within the 
nanoparticles. However, the results confirm release of pDNA in a slow manner when treated 
with reducing agent, which is advantageous regarding the protective properties, potentially 
prolonging therapeutic effects in vivo. The slow release indicates preserved functionality of 
the nanoparticles when loaded with the significantly larger plasmid DNA compared to AONs 
(Chapter 3). 
	
Figure 44. Reductive degradation and pDNA release from peptide nanoparticles (A); Agarose gels: 
release after 24 h incubation with 200 mM DTT (B); Release of pDNA monitored over 6 h (C).  
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4.3.4 Transfection Studies 
For testing the in vitro transfection performance of AcK6gA, K10gA, and H3SSgT peptide 
nanoparticles, they were loaded with GFP-encoding pDNA as reporter gene and 
subsequently applied to U87 cells. The transfection efficiencies were quantified via 
fluorescence levels of the expressed GFP. pDNA-loaded AcK6gA particles were formed using 
N/P-ratios of 5.5 and 20 to obtain slightly positively charged nanoparticles. For pDNA-
loaded K10gA nanoparticles N/P-ratios of 10 and 20 were used for transfection studies. The 
nanoparticles were incubated with U87 cells and GFP expression levels were assessed 24 and 
48 h after application using flow cytometry. Simultaneously, the populations of the gated 
cells (forward- vs. sidescattering) were determined, relative to a nontreated control, 
reflecting the compatibility of the nanoparticles with mammalian cells and potential toxicity 
caused by the peptide–pDNA constructs. These provide information about the ratio of viable 
cells to apoptotic, necrotic, and dead cells. The values were compared to Lipofectamine, 
applied at 0.5 µg/well due to optimization experiments (0.1–1.0 µg/well) revealing no 
increase in transfection efficiency at amounts above 0.5 µg/well (Figure 45). pDNA-loaded 
AcK6gA nanoparticles at an N/P-ratio of 5.5 were incubated with U87 cells to obtain 1.0 µg 
and 1.7 µg pDNA/well, respectively (Figure 46). At an N/P-ratio of 20, 1 µg pDNA/well 
were applied. Flow cytometry analysis of AcK6gA nanoparticles incubated for 24 h revealed 
6 % transfection and a relative population of around 65 % for both, 1.0 and 1.7 µg 
pDNA/well (N/P=5.5). At an N/P-ratio of 20 a transfection efficiency of 14 % was obtained 
with a drastically decreased population (18 %) relative to nontreated control cells. After 48 h 
incubation, the transfection reached 12 % and 24 % for 1.0 and 1.7 µg pDNA/well 
(N/P=5.5), respectively. The relative cell populations were calculated to 79 and 57 %. At 
N/P=20 transfection reached values of 41 % (relative population: 30 %). In comparison, the 
gold standard transfection agent Lipofectamine revealed transfection values of 25 and 45 % at 
24 and 48 h incubation, respectively, revealing relative populations of around 48 % (Figure 
46). The reverse proportionality of transfection efficiency and relative population with 
increasing pDNA amount and N/P-ratio can be attributed to the elevated levels of toxicity 
emerging from the positively charged particles interacting with the phospholipid bilayer of 
cell membranes.246 This surface charge dilemma is well known for transfection agents and 
remains a major challenge in the development of effective and nontoxic gene delivery 
systems.  
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Figure 45. Flow cytometry optimization of pDNA amount (A) and number of cells (B) per well in 24-
well cell culture plates for transfection experiments using Lipofectamine. 
Similarly, pDNA-loaded K10gA nanoparticles were investigated on their transfection 
performance and toxicity using U87 cells (Figure 47). Incubation for 24 h led to comparable 
transfection efficiencies of 16 % and 11 % for 1.0 and 2.0 µg pDNA/well (N/P=10), 
respectively. For nanoparticles at an N/P-ratio of 20 (1.0 µg pDNA/well) a transfection 
efficiency of 14 % was obtained. Populations relative to nontreated control cells were found 
at 57 % (1.0 and 2.0 µg pDNA/well; N/P=10) and 40 % (1.0 µg pDNA/well; N/P=20). 
When incubated for 48 h, K10gA nanoparticles showed the same tendencies as observed for 
AcK6gA nanoparticles: delivery of 1.0 and 2.0 µg pDNA/well (N/P=10) revealed 
transfections of 37 and 47 %, respectively. Particles with N/P=20 showed 58 % transfection. 
In contrast to AcK6gA-NPs, K10gA-NPs were less toxic to U87 cells, indicated by relative 
populations of around 65 % (Figure 47), more than twice as high as for AcK6gA 
nanoparticles. 
Transfection efficiency of pDNA-loaded H3SSgT nanoparticles was analyzed using 
previously determined N/P-ratio of 2, and compared to nanoparticles formed at an N/P-
ratio of 50. The peptide nanoparticles were applied at 0.8 and 1.5 µg pDNA/well and 
analyzed using flow cytometry (Figure 48). At an N/P-ratio of 2, only marginal transfection 
of 3–4 % was obtained (0.8 and 1.5 µg pDNA/well) while cell populations were not altered 
by the nanoparticles and remained at around 80 % relative to nontreated cells. When using 
nanoparticles at N/P-ratio of 50, transfection efficiency up to 15 % was achieved, but the 
relative population of gated cells decreased to 50 and 30 % for 0.8 and 1.5 µg pDNA/well, 
respectively. 
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Figure 46. Flow cytometry transfection efficiencies and relative populations of GFP-transfected U87 
cells using pDNA-loaded AcK6gA nanoparticles. Populations were gated according to a nontreated 
control. Each data point represents the average ±SD of two individual experiment comprising 104 cells. 
	
Figure 47. Flow cytometry transfection efficiencies and relative populations of GFP-transfected U87 
cells using pDNA-loaded K10gA nanoparticles. Populations were gated according to a nontreated 
control. Each data point represents the average ±SD of two individual experiment comprising 104 cells. 
# 1×104 cells. 
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The transfection efficiencies are very promising for both, AcK6gA and K10gA nanoparticles; 
however, limited compatibility with cells, probably due to positive surface charges, demand 
for further improvement of the present system. pDNA-loaded H3SSgT nanoparticles 
revealed lower transfection efficiencies, but showed higher relative populations compared to 
the polylysine-based nanoparticles. These results are in agreement with reversed 
proportionality of transfection efficiency and toxicity/noncompatibility observed for 
AcK6gA and K10gA nanoparticles. The obtained transfection efficacies reflect not only the 
potential of such nanoparticles as gene delivery vectors, but also underline the importance of 
fine-tuning the molecular design to avoid toxic effects. Further investigations are needed to 
find optimal conditions for purely peptidic gene transfection based on amphiphilic peptides 
comprising polylysine or polyhistidine combined with a gramicidin A derived sequence. 
	
Figure 48. Flow cytometry transfection efficiencies and relative populations of GFP-transfected U87 
cells using pDNA-loaded H3SSgT nanoparticles Populations were gated according to a nontreated 
control. Each data point represents the average ±SD of two individual experiment comprising 104 cells.  
GFP fluorescence of transfected cells was visualized using CLSM. The intense fluorescence 
signal for both constructs, AcK6gA (Figure 49C) and K10gA (Figure 49D), comparable to 
the positive control (Lipofectamine; Figure 49B) confirm the functionality of the present 
system. However, for all samples, including the positive control, a corny round shape of the 
cells was observed (Figure 49). This can be assigned to apoptotic cells and is in agreement 
with the decreased relative populations obtained from flow cytometry analysis. Therefore, 
further investigations are required to fully understand the diverse influences of the N/P-ratio 
and the nature of the nanoparticles on cell viability and transfection capability. 
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Figure 49. CLSM micrographs of GFP-transfected U87 cells. GFP emission (left), transmission 
(middle), and merge (right). Nontreated (negative control) (A), treated with Lipofectamine (positive 
control) (B), treated with pDNA-loaded AcK6gA nanoparticles (C), and treated with pDNA-loaded 
K10gA nanoparticles (D). 
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4.3.5 Toxicity Studies 
To further investigate toxic effects of the created gene transfection agents MTS- and 
propidium iodide-assays were performed, in order to compare the results with relative 
populations obtained from transfection experiments (Transfection Section). MTS-assays of 
H3SSgT nanoparticles did not show any toxic effects even when applied alone (nonloaded 
nanoparticles; Figure 34, Chapter 3). Here, viabilities were evaluated for H3SSgT 
nanoparticles loaded with pDNA at N/P-ratios of 10 and 30. None of the tested 
concentrations in the range of 5–50 µg/mL showed toxic effects (Figure 50A). Furthermore, 
AcK6gA and K10gA nanoparticles were assessed at an N/P-ratio of 5. The cell viability was 
not altered in the tested range of 5–50 µg/mL (Figure 50B). In addition to MTS-assays, 
AcK6gA and K10gA were examined at three different N/P-ratios using a Hoechst 33342–
propidium iodide assay, analyzed by flow cytometry to obtain the population of 
nonapoptotic cells. For both peptides lower N/P-ratios of 1 and 2 did not show apoptotic 
effects. In contrast, nanoparticles with an N/P-ratio of 10 revealed increased apoptosis for 
both, K10gA (62 % nonapoptotic cells) and AcK6gA (32 % nonapoptotic cells) (Figure 
50C). These values match the results from flow cytometry analysis (Transfection Section) 
and qualitative observations using CLSM. Nontreated controls revealed a nonapoptotic 
population of 81 % and Lipofectamine showed 63 % nonapoptotic cells. The disagreement of 
the MTS-assays with other techniques used to determine compatibility with cells 
demonstrates that individual experimental setups can significantly influence the results. In 
addition, the method related quantification procedures possibly favor certain results by e.g. 
excluding apoptotic cells. As indicated in Figure 49 the cells were able to produce GFP but 
revealed a corny apoptotic shape. Similarly, the metabolic activity might be still intact to 
convert the tetrazolium componds of the MTS-assay to formazan products, thereby 
reporting viable cells. However, toxicity is a frequently appearing problem in the 
development of gene delivery agents due to the nucleic acid condensing mechanism, 
requiring multiply charged carriers for achieving acceptable loading efficiency. Optimizing 
the developed system by reducing surface charges and fine-tuning peptide sequences 
potentially eliminate toxic effects of these nanoparticles and lead to a gene delivery system 
with high efficacy.  
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Figure 50. Viability of U87 cells treated with pDNA-loaded H3SSgT, AcK6gA, and K10gA 
nanoparticles. MTS assay of pDNA-loaded H3SSgT (N/P=10 and 30) (A) and AcK6gA and K10gA 
nanoparticles (N/P=5) (B). Hoechst 33342–propidium iodide assay of pDNA-loaded K10gA and 
AcK6gA nanoparticles at N/P-ratios of 1, 2, and 10 (C). Data represent average ± SD (n=3). 
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4.4 Conclusion 
The growing demand for nonviral gene delivery carriers requires smart nanoengineering of 
polycations. In the present study, novel vectors for pDNA delivery were developed and 
assessed on transfection efficiency and toxicity using GFP-encoding pDNA as a reporter 
gene. The carriers are based on a rational design of amphiphilic peptides to form 
nanoparticles after condensation of pDNA via electrostatic interactions. Peptide sequences 
were constructed from hydrophobic sequences derived from gramicidin A and combined 
with polylysine or polyhistidine that served as the condensing moieties. Three sequences 
were investigated: AcK6gA, K10gA, and H3SSgT. All peptides were capable of completely 
condensing pDNA at N/P-ratios of 2–10 forming particles with diameters of 40–60 nm. The 
slightly positive surface charge promote cellular uptake, and in case of H3SSgT endosomal 
escape is potentially supported by the histidines, which can buffer the proton sponge effect. 
pDNA-loaded H3SSgT nanoparticles revealed partial release of pDNA upon addition of 
reducing agent in a slow manner, possibly hindered by the size of the plasmid and the 
resulting entangled nanoparticle architecture. Nanoparticles assembled from lysine-based 
peptides revealed promising transfection efficiencies up to about 60 %, slightly higher 
compared to Lipofectamine (~ 50 %). Using pDNA-loaded H3SSgT nanoparticles a 
transfection efficiency of 15 % was achieved while preserving high relative population of 
gated cells referenced to nontreated cells. However, increasing positive surface charge 
simultaneously induced cytotoxicity, resulting in a reversed proportionality of transfection 
efficiency and toxicity. This is a widely reported phenomenon, challenging the development 
of efficient transfection agents and requiring a very careful adjustment of each individual gene 
delivery system. Further optimization of the presented peptide nanoparticles is necessary to 
eliminate toxicity while preserving transfection ability. 
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Chapter 5 
5 Nanoparticle-Based Highly Sensitive MRI 
Contrast Agents with Enhanced Relaxivity in 
Reductive Milieu 
In this chapter, a highly sensitive, reduction-responsive MRI contrast agent is described. 
The contrast agent is coassembled from gadolinium-complexed heparin-PDMS and 
reduction-sensitive peptides, forming nanoparticles. Relaxivities are assessed by a human 
clinical MRI scanner and compared to a commercial contrast agent. 
 
This chapter was submitted for publication: 
Sigg, S. J.; Santini, F.; Najer, A.; Richard, P. U.; Meier, W.; Palivan, C. G. Nanoparticle-Based Highly 
Sensitive MRI Contrast Agents with Enhanced Relaxivity in Reductive Milieu. 2016, submitted. 
	
Figure 51. Coassemblies of gadolinium-complexed heparin-PDMS and a reduction-responsive 
peptide revealing high contrast in MRI. In reductive milieu the coassembled peptide is degraded that 
further increases contrast due to increased accessibility of water to the metal centers. 
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5.1 Abstract 
Current magnetic resonance imaging (MRI) contrast agents often do not provide sufficient 
contrast for diagnosing early disease stages due to relatively low contrast efficacy. 
Additionally, sensing of biochemical environments by MRI probes is desirable to increase 
contrast even further. Here, we report a highly sensitive nanoparticle-based MRI probe with 
r1 relaxivity up to 51.7 ± 1.2 mM-1s-1. The nanoparticles with diameters of about 45 nm were 
self-assembled from gadolinium-complexed heparin-poly(dimethylsiloxane) copolymer. 
Responsiveness to reductive environments was additionally introduced by incorporation of a 
reduction-sensitive amphiphilic peptide to the previous nanoparticle architecture. The loss of 
peptide components within a reductive milieu leads to an r1 relaxivity increase, therefore 
creating a higher contrast in MRI. This nanoparticle-based MRI probe is further 
characterized by low cellular uptake (max. 5.4 %), no apparent cellular toxicity (tested up to 
1 mM Gd3+), absence of anticoagulation property (below detection limit), and high shelf 
stability (no increase in free Gd3+ over 7 months). In combination with the enhanced 
permeability and retention effect (EPR-effect), which is expected for nanoparticles with sizes 
around 50 nm, this highly sensitive MRI contrast agent serves as a promising probe for early 
diagnosis of cancer through possible accumulation and contrast enhancement within 
reductive extracellular tumor tissue.  
5.2 Introduction 
Magnetic resonance imaging (MRI) is a noninvasive technique widely used in diagnostics 
such as cardiovascular, neurological, and oncological imaging.166 It relies on the manipulation 
of the nuclear spin of water protons by an external magnetic field to obtain an image. 
Contrast is generated by tissue-dependent variations in the longitudinal (T1) and transverse 
(T2) relaxation times of the proton nuclear spin. In order to induce additional contrast, 
chemical MRI contrast agents (CAs) are widely used. These are paramagnetic species that 
shorten T1 and T2 of the surrounding water protons. When the induced decrease in T1 and T2 
is roughly the same, they are called positive CAs, in case T2 is altered to much higher extend, 
they are called negative CAs.265 Positive CAs are predominantly built from gadolinium ions 
(Gd3+). Gadolinium increases the signal by decreasing the T1 relaxation time of water in its 
close proximity. The capacity of a CA is usually described by its relaxivity (r), which is the 
change in relaxation rate (∆(1/Ti)) normalized to the molar gadolinium concentration 
([Gd]) (Equation 1).265 𝑟 = ∆ ! !!"  (6) 
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However, the toxicity of free gadolinium requires it to be administered as a chelate, which in 
turns decreases the number of coordination sites available to water molecules, thus limiting 
the contrast enhancement. To date, nine gadolinium-based CAs are approved for clinical 
use,152 typically revealing an r1 of about 4–5 mM-1s-1.151 Gadolinium-based CAs are small 
molecules, which passively distribute after their administration to patients.158 The contrast 
enhancement achievable through the use of commercially available Gd-CAs is limited by 
their low efficiency, demanding for high doses.151,266 To increase contrast enhancement of 
MRI CAs three main strategies are followed: modifying the chelator to increase free 
coordination sites at the metal center and thus exchange rates between bulk water and 
coordinated water; increasing concentration of gadolinium by accumulating multiple 
chelators within one molecule; and the formation of bulky assemblies to lower molecular 
tumbling (τR) as both, high water exchange rates and decreased molecular tumbling 
contribute to faster relaxation and higher contrast.166 In this regard, nanosized 
macromolecular MRI probes of various architectures were reported, comprising 
micelles,267,268 dendrimers,269,270 vesicles,271-273 and nanoparticles.166,274,275 These exhibit higher 
relaxivities and allow for the introduction of stimuli responsiveness or combination with drug 
delivery for theragnostic approaches.276 
Introducing specificity and responsiveness of the MRI CAs to distinct body environments, 
such as inflamed tissue or tumor microenvironments, allow for specific localization of 
pathogenic regions and diagnosis.166,277 Therefore, individual gadolinium chelates were 
conjugated to build larger structures bearing high numbers of gadolinium-chelates, 
simultaneously decreasing τR due to their size and rigidity.  Both characteristics, high water 
exchange rates at the metal center and decreased molecular tumbling are contributing to fast 
relaxation of coordinating water molecules, creating higher contrast in MRI.166  
However, moderate contrast enhancement and/or lacking responsiveness to specific triggers 
were main drawbacks encountered with these novel designs.166 CAs able to respond to 
environmental characteristics of tissue, such as pH and redox potential, were developed in 
the past decade.278 Recent reports describe polymer shielded gadolinium oxide nanoparticles 
revealing an r1 of around 6.5 mM-1s-1 after release of the polymer at acidic pH due to an 
increase in water exchange rate, compared to 0.7 mM-1s-1 at neutral pH.279 Using the same 
principle, reducible cyclodextrin nanocapsules were constructed to entrap gadolinium-
chelates. Reductive release of the chelates increased tumbling as the dominant factor, thus 
decreasing r1 from 15.2 mM-1s-1 to 8.2 mM-1s-1.280 Another approach describes the activation 
of gadolinium-chelate monomers to polymerize and self-assemble when adding reducing 
agent, what increased r1 from 3.9 mM-1s-1 to 8.3 mM-1s-1.281 These values are comparably small 
in regard of theoretically possible relaxivities151 and are in the range of commercially available 
contrast agents (~ 4–5 mM-1s-1).151 CAs combining high r1 relaxivity and responsiveness to 
physiological parameters at pathologic sites remains a major challenge. 
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In this respect, our aim herein is to develop a highly active and reduction-sensitive MRI 
contrast agent. Trivalent lanthanides, including gadolinium, were reported to have high 
affinity toward the glycosaminoglycans (GAGs) heparin282,283 and hyaluronan (HA).284 In 
addition, transchelation of gadolinium from FDA-approved, linear contrast agents to heparin 
was observed, indicating strong complexing abilities of this particular GAG.285 Furthermore, 
heparin is a possible candidate to be exposed on nanoparticles for prolonged circulation time 
within the blood stream.286,287 This allows using reduced doses of MRI CAs and efficient 
vasculature imaging at longer time scales.274,276 Long-circulating nanoparticles can readily 
accumulate in tumor tissue via the leaky vasculature surrounding tumors (EPR-effect),288,289 
which increases efficacy of cancer imaging.290,291 The elevated GSH-levels in the extracellular 
environment of tumors, compared to nonmalignant cell, can be chosen as trigger to increase 
image contrast.292,293 
Therefore, we designed and synthesized an amphiphilic heparin-poly(dimethylsiloxane) 
(hepPDMS) block copolymer being capable of self-assembling into nanoparticles and 
offering complexation sites for gadolinium. In order to implement responsiveness towards 
environments with increased reducing properties, a disulfide linked amphiphilic peptide was 
synthesized via SPPS on a Rink amide resin. This peptide was then coassembled with 
previously complexed hepPDMS-Gd copolymer to obtain a reduction-sensitive MRI CA. 
The peptide sequence bears a reducible linker connecting the hydrophobic L-tryptophan-D-
leucine repeating unit and the oligohistidine (H3SSgT) as reported in Chapter 3. The 
amphiphilic peptide was designed to interact with hepPDMS-Gd via the polyhistidine 
sequence to coassemble into peptide-hepPDMS-Gd nanoparticles (p-hepPDMS-Gd-NPs). 
This novel approach using natural chelators for developing a highly sensitive nanoparticulate 
MRI CA and additionally implement sensitivity to reducing environments via coassembly 
with a peptidic component offers a promising direction for future optimization and 
application of these nanoparticles. 
5.3 Results and Discussion 
5.3.1 Gadolinium Complexation, Nanoparticle Formation, and 
Characterization 
Inspired by the strong Gd3+ complexing ability of the natural GAG heparin282,285 and the long 
blood circulation behavior of heparinized nanoparticles286,287 we designed a heparin-based 
nanoparticle system intended for highly sensitive MRI contrast enhancement. We 
synthesized an amphiphilic heparin-poly(dimethylsiloxane) (hepPDMS) copolymer, which 
self-assembles into nanoparticles under aqueous conditions.294 HepPDMS was obtained by 
coupling commercial heparin polysaccharide with commercial PDMS (5 kDa) via reductive 
 Chapter 5 
  81 
amination, which typically yielded 25 heparin repeating units per PDMS chain (5 kDa), as 
previously reported.294 HepPDMS nanoparticles (hepPDMS-NPs) were subsequently 
formed by the solvent exchange method, starting from 50% ethanol to water via dialysis. 
Similarly to previously reported self-assemblies formed by hepPDMS in PBS,294,295 the 
obtained assemblies revealed a small spherical nanoparticle morphology (transmission 
electron microscopy (TEM), 19 ± 3 nm, and dynamic light scattering (DLS), 44 ± 16 nm) 
(Figure 61A,B (Supporting Information)). The observed size difference between TEM and 
DLS can be attributed to the drying effect in TEM. The accessibility of heparin on the surface 
of the NPs was quantified by the Farndale microassay giving a concentration of accessible 
heparin of 1170 ± 42 µg/mL for nanoparticles built from an initial hepPDMS concentration 
of 4.25 mg/mL.  
	
Figure 52. Schematic representation and TEM micrographs of hepPDMS-Gd-NPs (A), p-hepPDMS-
Gd-NPs before (B), and after (C) addition of DTT. Scale bars: 200 nm. 
To create a nanoparticle-based gadolinium MRI CA, hepPDMS was incubated with a 
solution of GdCl3 (6.5 eq.) in 50% ethanol at pH 7.0 in order to complex Gd to the heparin 
block of the copolymer, which comprises highly negative charged trisulfated disaccharide 
repeating units, reported to possess high affinity to lanthanides.282,283 Nanoparticles were 
obtained as described above, whereas non-complexed gadolinium was simultaneously 
removed during the dialysis step, yielding hepPDMS-Gd nanoparticles (hepPDMS-Gd-
NPs). DLS and TEM measurements showed particles sizes of 51 ± 22 nm and 45 ± 16 nm 
(Figure 60 (Supporting Information) and Figure 52A), respectively. The shift in size 
compared to hepPDMS-NPs (Figure 61A,B (Supporting Information)) can be attributed to 
decreased surface charges lowering the repulsive force between molecules, thus allowing a 
more dense structure. Successful complexation of gadolinium to the heparin-block of 
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hepPDMS-NPs was shown by Fourier transform infrared spectroscopy (FTIR). A frequency 
shift to lower values as well as peak line shape broadening is expected in FTIR when metals 
have bound to the heparin block.296  
FTIR showed the O-H stretching at 3440 cm-1, C=O stretching vibrations at 1626 cm-1, N–H 
bending at 1410 cm-1, and symmetrical (1240 cm-1) and asymmetrical (1043 cm-1) stretching 
of the S=O bond (NH–SO3– and CH2–SO3–)297 of heparin for hepPDMS-NPs (Figure 
53A). The slightly decreased frequencies for these functional groups, when complexed with 
gadolinium (hepPDMS-Gd), as well as broadening of the peaks indicated interaction of 
gadolinium to the heparin of hepPDMS.  The absorption at 1100 cm-1 is the asymmetric and 
symmetric stretching of two siloxane bonds of the PDMS block, which remained the same 
after complexation with gadolinium. The signal at 800 cm-1 is the out-of-plane and at 1259 
cm-1 the in-plane bending or scissoring vibrations of Si–CH3 of the PDMS block (Figure 
53A).298 This confirms that no interaction occurred between the hydrophobic block of the 
copolymer and gadolinium, as expected.  
	
Figure 53. FTIR spectra of hepPDMS-NPs and hepPDMS-Gd-NPs (A). Grey dashed lines are the 
PDMS absorptions; grey regions indicate the gadolinium interaction to the heparin block. Surface 
accessible heparin as measured by Farndale microassay (B). Data represent average ± SD (n=3). 
Complexation of gadolinium to the heparin block of hepPDMS was further confirmed by a 
Farndale microassay that showed significant decrease of accessible heparin chains on 
nanoparticles from 1170 ± 42 µg/mL (hepPDMS-NPs) to 960 ± 49 µg/mL (hepPDMS-Gd-
NPs) due to partial occupation of the dye-binding sites on heparin by Gd3+ (Figure 53B). 
The concentration of gadolinium complexed within the hepPDMS-NPs was determined to 
be 0.93 mM by inductively coupled plasma optical emission spectroscopy (ICP-OES), which 
is 77 % of the initial gadolinium concentration. It demonstrates the high complexing abilities 
of hepPDMS and allows for creation of a high gadolinium-density within the nanoparticles, 
necessary for contrast enhancement in MRI.  
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In order to introduce additional reduction-sensitivity to our nanoparticle-based MRI CA the 
reduction-responsive amphiphilic peptide H3SSgT (0.5 mg/mL) was coassembled with 
previously complexed hepPDMS-Gd to yield p-hepPDMS-Gd-NPs. The formed 
nanoparticles were similar in size (TEM: 43 ± 10 nm; DLS: 57 ± 38 nm) and shape 
compared to hepPDMS-Gd-NPs (Figure 60 (Supporting Information) and Figure 52B). 
They are around four fold smaller compared to particles assembled from peptide (H3SSgT) 
alone (190 nm; Chapter 3), indicating that the obtained nanoparticles were coassembled 
from both hepPDMS-Gd and H3SSgT. A negligible population of larger intensity weighted 
diameters (>300 nm) was also observed and can be attributed to purely peptidic 
nanoparticles. Using higher concentrations of peptide (2 mg/mL) induced formation of 
large aggregates coexisting beside the coassemblies (Figure 61C,D). Therefore, further 
characterization of coassemblies was conducted using the lower peptide concentration (0.5 
mg/mL).  
Energy dispersive X-ray spectroscopy (EDX) analysis showed colocalization of gadolinium 
and sulfur (from the disulfide in the peptide and from hepPDMS) within the particles 
(Figure 54). The expected interaction of histidine residues of the peptide with the heparin 
block of hepPDMS when coassembled was analyzed using Farndale microassays. The 
coassembled peptide decreased the accessibility of heparin from 1020 ± 82 µg/mL to 760 ± 
85 µg/mL heparin. Since the assay monitors the accessible heparin, the cationic dyes used in 
the assay need to align on heparin to produce a signal, the values represent the situation on 
the surface of the nanoparticles rather than in their core. Thus, it also demonstrates the steric 
hindrance originating from the coassembled peptides. Zeta potential measurements revealed 
slightly different values of –55.0 ± 0.5 mV for p-hepPDMS-Gd-NPs compared to NPs 
assembled without peptide –58.0 ± 0.3 mV (hepPDMS-Gd-NPs). However, the changes in 
zeta potential are rather small emerging from the fact that heparin is the most negatively 
charged biological macromolecule.299 At H3SSgT/hepPDMS-Gd ratios suitable for 
coassembly the amount of histidines is not sufficient to neutralize the charge of heparin, 
resulting highly negatively charged NPs. The preservation of heparin-characteristic on the 
nanoparticle surfaces after Gd-complexation and self-assembly provides the desired 
properties for potential prolonged blood circulation time,286,287 required for accumulation in 
tumor regions via the EPR-effect and subsequent contrast enhancement for MRI 
diagnostics.290,291 
To characterize size and morphology changes of p-hepPDMS-Gd-NPs upon reductive 
stimuli, they were treated with 10 mM dithiothreitol (DTT) in HEPES buffer at pH 7.2 
resulting in slightly decreased diameters of 41 nm ± 8 nm by TEM and 44 ± 19 nm by DLS, 
as compared to hepPDMS-Gd-NPs (Figure 60 (Supporting Information) and Figure 52C). 
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Figure 54. EDX-spectra of Gd-DOTA (A), hepPDMS-Gd-NPs (B), and p-hepPDMS-Gd-NPs (C). 
5.3.2 MRI-Analysis 
The suitability of these Gd3+-complexed nanoparticles for decreasing the T1 relaxation time 
of surrounding water, thus increasing r1 for better MRI contrast, was investigated on a 3 T 
human clinical MRI scanner. As a reference we tested commercial gadolinium–1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (Gd-DOTA), which is one of the most 
frequently applied clinical MRI CA. Gd-DOTA revealed T1 relaxation times in a range of 
1360 ms at 0.10 mM gadolinium and 213 ms at 0.99 mM gadolinium (Figure 55, Table 6 
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(Supporting Information)), resulting in an r1 of 4.5 ± 0.1 mM-1s-1 (Figure 56), which is in 
agreement with literature values.150 When gadolinium was complexed within hepPDMS 
nanoparticles the water relaxation time was tremendously decreased ranging from 164 ms at 
0.093 mM to 20.2 ms at 0.93 mM. This resulted in an r1 value of 51.7 ± 1.2 mM-1s-1, which is 
more than an order of magnitude higher than for clinically used Gd-DOTA. This can be 
attributed to the different binding mode of gadolinium to heparin compared to the cyclic 
DOTA, creating faster exchange rates at the metal centers and decreased tumbling due to the 
size of the nanoparticles.  
	
Figure 55. T1 weighted MR image of Gd.DOTA, hepPDMS-Gd-NPs, p-hepPDMS-Gd-NPs (–DTT), 
and p-hepPDMS-Gd-NPs (+DTT), recorded on a 3 T human MRI scanner. Detailed gadolinium 
concentrations of the different nanoparticles are summarized in Table 6 (Supporting Information). 
	
Figure 56. 1/T1 curves (A) and 1/T2 curves (B) of p-hepPDMS-Gd (–DTT), p-hepPDMS-Gd 
(+DTT), and Gd-DOTA. Slopes provided the r1 and r2 as indicated. 
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When coassembled with the reduction-responsive H3SSgT, p-hepPDMS-Gd-NPs revealed 
higher T1 values ranging from 154 ms at 0.11 mM gadolinium to 20.8 ms at 1.10 mM 
gadolinium (Figure 55, Table 6 (Supporting Information)), resulting in a decreased r1 of 
44.2 ± 1.5 mM-1s-1 compared to purely hepPDMS-Gd-based nanoparticles. This can be 
associated with increased density within the coassembled particles due to close arrangement 
of the peptidic histidines to the heparin block of the copolymer, thereby sterically hindering 
water to access and coordinate to the metal centers, which decreases relaxivitiy. After 
treatment with reducing agent (DTT) the T1 relaxation times significantly changed back 
towards lower values ranging from 124 ms at 0.11 mM gadolinium to 16.7 ms at 1.06 mM 
gadolinium (Figure 55, Table 6 (Supporting Information)). Releasing the coassembled 
peptide by reduction revealed an increase in r1 of about 20% to 54.4 ± 1.5 mM-1s-1 (Figure 
56), which is again close to the value of NPs assembled from hepPDMS-Gd alone. This 
increase in relaxivity observed in reductive environment can be used to obtain increased 
contrast for cancerous tissue based on the elevated GSH-levels in extracellular space of 
tumors.292,293 The slight difference compared to hepPDMS-Gd-NPs can be explained by the 
lack of a highly ordered assembly due to the degradation and dissociation of one assembly 
partner. Analysis of T2 relaxation rates revealed similar tendencies, when compared to Gd-
DOTA. For hepPDMS-Gd-NPs a transverse relaxation rate, r2, of 162.6 ± 17.8 mM-1s-1 was 
obtained. For particles coassembled with H3SSgT, r2 was determined to be 103.5 ± 5.0 mM-
1s-1 and 108.4 ± 2.5 mM-1s-1 after DTT-treatment. These values are, similar to the increase in 
r1, more than one order of magnitude higher, compared to Gd-DOTA (4.90 ± 0.03 mM-1s-1).  
5.3.3 EPR-Analysis 
In order to further characterize the ability of the created contrast agent to decrease T1 and T2 
as demonstrated by MRI analysis, we performed EPR measurements to obtain the transverse 
electronic relaxation time (T2e), which is expected to reveal lower values for gadolinium-
complexed nanoparticles compared to Gd-DOTA. Gadolinium has an 8S7/2 single ion ground 
state and a nuclear spin value of 1/2. The spin Hamiltonian of the Gd3+ ion is based on the 
Zeeman electronic interaction and the zero-field interaction: ℋ = 𝑔𝛽𝐵𝑆 + 𝐷 𝑆!! − !! 𝑆 𝑆 + 1 + 𝐸 𝑆!! − 𝑆!!  (7) 
where g is the gyromagnetic factor of the S-state, D and E are the zero-field splitting (ZFS) 
parameters.300 If the system is characterized by a strong Zeeman interaction, significantly 
higher than the crystal field, the EPR spectrum appears as a single very broad line with a 
g-factor of around 2.00. In the opposite situation in which the crystal field is strong, the EPR 
spectrum is complex with additional lines appearing both with g-values significantly higher 
than 2 and lower than 2. In the case of Gd-complexed nanoparticles (hepPDMS-Gd-NPs and 
p-hepPDMS-Gd-NPs) and Gd-DOTA the EPR spectra at 298 K have gyromagnetic factors 
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of around 2.00 within experimental errors (Table 7 (Supporting Information)), with no 
additional lines at higher or lower g-values (Figure 57). Compared with Gd-DOTA 
spectrum, the EPR spectra of coassemblies consist of very broad lines. They differ from 
Lorenzian lines, and might be described as a superposition of two lines with different 
intensity and peak-to-peak widths, as already reported for Gd-complexes in aqueous solution 
(Figure 57).301 EPR line widths (ΔHpp) allow the calculation of the transverse electronic 
relaxation rates, 1/T2e using Equation 8:302 
!!!! = !!!! !! 𝛥𝐻!!  (8) 
Where µB is the Bohr magneton, and h the Plank constant. The more intense paramagnetic 
component has been taken into account when ΔHpp have been calculated. The relaxation rate 
at a field of 0.34 T for Gd-DOTA was calculated as 1.31×109 s-1,303 whilst the relaxation rates 
for hepPDMS-Gd-NPs, and p-hepPDMS-Gd-NPs were 6.56×109 s-1, and 5.98×109 s-1, 
respectively. 
	
Figure 57. EPR spectra of Gd-DOTA (A), hep-PDMS-Gd-NP (B), and p-hep-PDMS-Gd-NP (C). 
The significant difference between the transverse electron spin relaxation rate corresponding 
to Gd-DOTA and those of Gd-complexed NPs indicate that intramolecular dipole-dipole 
interactions between close Gd(III) ions in the case of Gd-complexed NPs induce the 
decrease of T2e,304 in addition to a slower rotational correlation time due to the difference in 
their size. Our results are in agreement with previous reports indicating that the increased 
proton relaxivity was associated with the formation of rigid micelle-like structures in aqueous 
solution.302 The slight difference in the transverse electron spin relaxation rate between 
hepPDMS-Gd-NPs and p-hepPDMS-Gd-NPs indicate an effect of the coassembled peptide, 
as it has been intended in order to decrease Gd accessibility. Given the lack of a reliable 
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theory of electron spin relaxation for macromolecular Gd-systems, especially in a complex 
system as the Gd-complexed NPs we point out only in a qualitative manner that 
intramolecular dipole-dipole mechanism contributes to the electronic relaxation. D-values 
were estimated based on the ΔB values between the central line and the edge line of lower 
magnetic field in the EPR spectrum (the supposed position of this line to induce the 
significant broadening of the overall line), and using a formula valid in the first order of the 
perturbation theory: D=ΔB/6. Electronic relaxation in Gd3+ complexes is generally explained 
in terms of a zero-field splitting interaction. However, due to the broad EPR overall shape, 
the ZFS tensors contribute only to enlargement of the EPR linewidth and therefore, a precise 
estimation was not possible (we restrict only to the estimation of ΔHpp). 
5.3.4 In Vitro Evaluation 
The promising increase in relaxivity r1 of hepPDMS-Gd-NPs, p-hepPDMS-Gd-NPs, and 
DTT-treated p-hepPDMS-Gd-NPs indicate their potential for high contrast in MRI. A first 
obstacle to address is nonspecific cellular toxicity. This was tested in cell viability studies 
using HeLa cells and various concentrations of p-hepPDMS-Gd-NPs, hepPDMS-Gd-NPs, 
and commercial Gd-DOTA. None of the particles revealed any cellular toxicity at the tested 
concentration range up to about 1.0 mM gadolinium (Figure 58A). The absence of cellular 
toxicity could be attributed to low cellular uptake based on the highly negative surface charge 
on our nanoparticles. This was tested by incubation of hepPDMS-Gd and p-hepPDMS-Gd 
nanoparticles with HeLa cells, subsequent washing, digestion and quantification of Gd 
content using ICP-OES. We found only marginal uptake of 2.8 and 5.4 %, respectively 
(Figure 58B). This is advantageous due to desired long-circulation time within the blood 
stream, for which low cellular uptake is needed, and subsequent fast removal from the body. 
	
Figure 58. MTS viability assay of HepPDMS-Gd-NPs and p-hepPDMS-Gd-NPs compared to 
commercial contrast agent Gd-DOTA (A). Cell uptake of hepPDMS-Gd-NPs and p-HepPDMS-Gd-
NPs (B). Data represent average ± SD (n=3) (A); average ± 10% deviation by ICP-OES (B). 
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Leakage of free gadolinium ions from the nanoparticles is associated with toxicity concerns 
and represents another hurdle for translation towards an in vivo applicable MRI CA. Free 
gadolinium ions in solution were quantified using a xylenol orange colorimetric assay. 
HepPDMS-Gd-NPs showed 8.5% free gadolinium relative to the total amount, whereas p-
hepPDMS-Gd-NPs revealed 5.9% free gadolinium. After incubation for seven months at 
room temperature the level of free gadolinium was not elevated (8.3% and 5.6%, 
respectively); however, the nanoparticles partly rearranged to larger sizes, particularly for 
peptide coassemblies (Figure 59). This can be explained by slow sedimentation and 
subsequent aggregation of the nanoparticles.  Stability of the nanoparticles was also 
investigated by incubation in cell growth media. The sensitivity of the assay was limited due 
to cross interaction of the colorimetric assay with the culture media. Nevertheless, the 
measured gadolinium levels remained below the detection limit of about 1 µM. This level can 
be seen as noncritical regarding the normally applied concentrations of 0.1–0.3 mmol/kg305 
for commercial MRI CAs with an r1 of 4–5 mM-1s-1 and LD50 values for gadolinium of 0.5 
mmol/kg in rats.306  
	
Figure 59. Free Gadolinium before and after incubation for 7 months at room temperature (A). Size 
distribution after incubation for 7 months (B).	
The third obstacle for our nanoparticle system is the known anticoagulation property of 
heparin, which we want to avoid for MRI imaging applications. The anticoagulation activity 
was evaluated using standard anti-Xa assays. Anticoagulation activity was below the limit of 
detection of the assay (<0.1 U/mL) for hepPDMS-Gd-NPs and p-hepPDMS-Gd-NPs at 
concentrations of 700 and 580 µg/ml accessible heparin (=135 and 110 U/ml), respectively. 
This indicates that the anticoagulation ability of heparin was greatly reduced by conjugation 
to PDMS and subsequent nanoparticle formation. The specific pentasequence of heparin 
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needed for anticoagulation activity might be mainly hidden within the self-assembled 
nanostructures. The developed reduction-sensitive constructs serve as a very promising 
candidate toward functional high-relaxivity MRI CAs. 
5.4 Conclusion 
Responsive high-relaxivity MRI contrast agents are highly demanded for clinical diagnostics. 
P-hepPDMS-Gd-NPs fulfill numerous key criteria for being used as responsive high-
relaxivity CAs. The developed CAs coassembled from gadolinium-complexed hepPDMS and 
reduction-sensitive peptide H3SSgT, forming spherical nanoparticles with diameters of 
about 45 nm. These nanoparticles revealed an r1 relaxivity of 44.2 mM-1s-1, that is tenfold 
higher compared to the gold standard Gd-DOTA (4.5 mM-1s-1). Treatment of the particles 
with reducing agent increased r1 by about 20% to 54.4 mM-1s-1. The high levels of r1 allow use 
of significantly lower doses while preserving enough contrast for diagnostics. In addition, the 
triggered enhancement of r1 enables localization of regions with increased reduction 
potential, such as cancerous tissue. In vitro cell assays demonstrated low cellular uptake and 
absence of cellular toxicity of the assembled nanoparticles. Furthermore, they did not show 
any anticoagulation activity in vitro and the stability at room temperature is provided for at 
least seven months, as demonstrated by constant levels of free gadolinium. All these 
characteristics make our reduction-sensitive coassemblies a promising candidate to be used 
as functional high-relaxivity MRI CAs. 
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5.5 Supporting Information 
5.5.1 Nanoparticle Characterization 
	
Figure 60. DLS of gadolinium-complexed nanoparticles. HepPDMS-Gd-NPs (broken line), 
p-hepPDMS-Gd-NPs before (dashed line), and after (dotted line) treatment with DTT. 
	
Figure 61. DLS (A) and TEM (B) of hepPDMS-nanoparticles. DLS (C) and TEM (D) of 
coassemblies formed by using 2 mg/mL H3SSgT peptide. Scale bars: 200 nm.  
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5.5.2 MRI data 
Table 6. Concentrations, longitudinal (T1) and transversal (T2) relaxation times of Gd-DOTA, 
hepPDMS-Gd-NPs, p-hepPDMS-Gd-NPs (–DTT), and p-hepPDMS-Gd-NPs (+DTT).	
 Gd-concentration 
(mM) 
T1  
(ms) 
T2  
(ms) 
Gd-DOTA 0.986  213  204 
0.591  334  341 
0.296  632  680 
0.099 1360  1870 
hepPDMS-Gd-NPs 0.930  20.2  6.8 
0.558  31.9  14.9 
0.279  59.8  30.5 
0.093  164  94.9 
p-hepPDMS-Gd-NPs (–DTT) 1.057  20.5  9.2 
0.634  31.6  17.0 
0.317  57.9  33.6 
0.106  154  98.5 
p-hepPDMS-Gd-NPs (+DTT) 1.057  16.7  8.7 
0.634  25.9  15.2 
0.317  48.6  30.7 
0.106  124  86.8 
5.5.3 EPR data 
Table 7. EPR parameters and transverse electronic relaxation rates (T2e) of Gd-DOTA and Gd-
complexed NPs. 
Complex g ΔHpp (G) T2e (ns) 
Gd-DOTA  1.980  96  0.77 
hepPDMS-Gd-NPs  2.003  430  0.15 
p-hepPDMS-Gd-NPs  2.013  390  0.17 
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Chapter 6 
6 General Conclusion and Outlook 
In this thesis, short amphiphilic peptides were designed for various biomedical applications. 
Peptides are particularly interesting due to their intrinsic biocompatibility and 
biodegradability, which are essential for in vivo applicability. The peptide sequences were 
constructed utilizing gramicidin A inspired hydrophobic regions combined with hydrophilic 
regions featuring desired and tailor-made properties and functionalities for intended 
application. Two different hydrophobic regions were used: gA and gT. The sequence of gA is 
similar to gramicidin A, whereas the gT sequence is based on a truncated version bearing the 
essential L-tryptophan-D-leucine repeating unit, exhibiting a β-turn secondary structure in 
aqueous solution. This specific spatial arrangement generates a highly hydrophobic character 
by hiding the peptidic backbone in the inner core and presenting the side chains (tryptophan 
and leucine) to the outer environment. In this thesis four projects were conducted, each with 
different requirements of peptide properties and features. 
The first project aimed for the production of peptide nanoparticles for theragnostic purposes, 
i.e. condensing diagnostic and therapeutic requirements down into one nanoparticle design. 
An elegant way is the incorporation of gold nanoparticles, due to their high optical density 
and thermoplasmonic properties. The former allows detection in diagnostic imaging, the 
latter enables triggered release of entrapped payload upon external stimuli, such as near 
infrared light. Nanoparticle-forming amphiphilic peptides were C-terminally modified with 
cysteine for binding to gold nanoparticles, thereby allowing them to subsequently assemble 
to composite peptide–gold nanoparticle superstructures. The obtained densely packed gold 
nanoparticle superstructures contain individual gold nanoparticles separated by a peptide 
bilayer. We proved that these amphiphilic peptides are capable of serving as scaffolds for gold 
nanoparticles, highlighting the strong driving forces to self-assemble in aqueous solution. 
These nanoparticles mighty find application in diagnostics, being used for probing cellular 
uptake pathways, or for real-time drug delivery imaging. 
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The second project focused on creating a codelivery carrier for antisense oligonucleotides 
and small molecule drugs. Such systems are crucial for combined treatments to combat 
multidrug resistance or to exploit synergistic effects of drug–gene or drug–drug 
combinations. Therefore, amphiphilic peptides were engineered bearing moieties to 
condense nucleic acid payloads and/or hydrophilic payloads and a hydrophobic region able 
to entrap small drugs upon self-assembly. The peptides were further equipped with a 
reduction-sensitive linker for triggered decomposition and cargo release in physiologic 
conditions at diseases sites. Straightforward rational design combining desired features 
within one peptide sequence led to noncytotoxic peptide nanoparticles with sizes optimal for 
biomedical applications (100–150 nm). The created nanoassemblies were able to carry 
hydrophilic, nucleic acid, and hydrophobic payloads. Further, they revealed high coloading 
efficiency and were highly sensitive to reductive trigger releasing both payloads in a fast 
manner. This novel codelivery system is further characterized by effective cell uptake (with 
and without serum) and high therapeutic efficacy delivering the hydrophilic model drug 
DoxHCl. Further investigations towards application and therapeutic effects in vivo will prove 
the functionality of the developed system and support the versatile applicability. 
The third project addressed the development of amphiphilic peptides bearing polylysine 
hydrophilic regions to achieve gene transfection in vitro. Two peptides were assessed, 
carrying different lengths of polylysine coupled to a gA sequence and compared to the 
peptide designed in the second project (H3SSgT). All peptides showed good plasmid DNA 
condensing abilities and formed nanoparticles in appropriate sizes for biomedical 
applications. Subsequent transfection experiments revealed high efficiencies. However, due 
to high positive charge excess cytotoxicity emerged when applied to cells. The cytotoxicity 
increased proportionally to the transfection efficiency, which might be explained by 
permeabilization of cell membranes by the lysines, allowing nanoparticles to pass and induce 
production of mRNA while the survival rate decreased significantly. Apart from the negative 
effects on cells under these particular conditions, the presented purely peptidic nanoparticle 
architectures show very promising potential towards highly potent gene transfection agents. 
However, further optimization and fine-tuning is necessary to obtain nontoxic gene delivery 
carriers with high efficacy. Promising strategies include the combination of lysines and 
histidines in the hydrophilic sequence featuring strong DNA condensation abilities, cell 
uptake and endosomal escape while excessive surface charge is prevented. Moreover, 
introduction of nuclear localization sequences could possibly lead to more effective transport 
through the nuclear pores, thereby enhancing efficiency. 
The fourth project aimed at the development of a highly sensitive MRI contrast agent. 
Therefore, we used an amphiphilic block copolymer bearing a hydrophilic block of heparin, 
known to possess high affinity to trivalent lanthanides such as gadolinium. Gadolinium is 
widely used as a positive contrast agent to increase contrast in MRI due to its high 
paramagnetism. The heparin was combined with a hydrophobic block of 
poly(dimethylsiloxane) to obtain an amphiphilic block copolymer that self-assembles into 
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nanoparticles. The constructed contrast agent revealed relaxivities of more than one order of 
magnitude higher (44 mM-1s-1) compared to commercially available contrast agents 
(~4 mM-1s-1). For achieving triggered contrast enhancement, the copolymer was 
coassembled with a reduction responsive amphiphilic peptide. Physiologic amounts of 
reducing agent resulted in a relaxivity increase from 44 to 54 mM-1s-1, which is about 20%. 
Important properties such as its nontoxicity, lack of anticoagulation activity, and stability 
over seven months regarding gadolinium release suggest this reduction-responsive highly 
sensitive MRI contrast agent as very promising candidate for selective contrast enhancement 
at disease sites. 
In summary, the present dissertation demonstrates, that rational design of amphiphilic 
peptides can lead to multifunctional, biocompatible, and biodegradable nanoarchitectures 
self-assembled in a well-defined manner. Functionality is introduced by point mutations in 
the peptide sequence; however, caution must be taken because small changes in the primary 
sequence can strongly influence the subsequent secondary structure and self-assembly 
behavior. The projects presented here provide an array of tailor-made amphiphilic peptides, 
tuned to distinct properties required for their intended applications. The presented results 
strongly suggest further studies exploring biologic and pharmacologic parameters such as 
biocompatibility, biodistribution, and circulation times to advance these systems to in vivo 
applications with high therapeutic and diagnostic efficacy. Furthermore, the diverse 
functionalities could be extended and/or combined toward theragnostic systems by e.g. 
combining MRI contrast enhancement capability with triggered codelivery performance. 
Also, using payloads, which are known to exhibit synergistic effects when applied in 
combination would allow to thoroughly evaluating the benefits of these nanoparticles 
regarding the therapeutic efficacy. Future research activities must also focus on the 
modification of these nanoparticles with specific targeting moieties to further advance their 
multifunctionality and specificity. Targeting moieties can be introduced as part of the peptide 
sequence or linked to the peptide post-synthesis. Furthermore, functionalization of the 
nanoparticles with nuclear localization sequences might enhance the efficiency of gene 
delivery to cell nuclei due to better transport across the nuclear envelope.  
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Chapter 7 
7 Experimental 
7.1 Materials 
All reagents and materials were of the highest commercially available grade and were used 
without further purification, unless mentioned differently. Rink Amide AM resin (0.71 
mmol/g), 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluoro-
phosphate (HCTU) and Fmoc-Trp(Boc)-OH were obtained from IRIS Biotech GmbH. 
Boc-Cystamine-Suc-OH was purchased from IRIS Biotech GmbH and converted into Fmoc-
Cystamine-Suc-OH amino acid as described previously.307 Other amino acids were 
purchased from Novabiochem. Dimethylformamide (DMF) was obtained from J.T. Baker, 
ethanol (96 %) F15 and dichloromethane from Brenntag Schweizerhall AG, 
N,N-diisopropylethylamine (DIPEA) from VWR, and acetonitrile (ACN) from Fisher 
Scientific. BODIPY 630/650 was purchased from Invitrogen. Atto550-labeled, 22-mer 
oligonucleotide (5' TAA CAG GAT TAG CAG AGC GAG G3') was obtained from 
Microsynth. Doxorubicin hydrochloride (DoxHCl) (98%) was purchased from Beijing 
Zhongshuo Pharmaceutical Technology Development Co., Ltd. (China). DMEM, fetal 
bovine serum, Opti-MEM, and penn/strep were obtained from Gibco. CellTiter 96 
AQueous One Solution Cell Proliferation Assay (MTS) was purchased from Promega. 
FCCS standard double-labeled DNA was obtained from IBA (Göttingen, Germany). 
Heparin sodium salt from porcine intestinal mucosa (15 kDa, 193 U/mg) was purchased 
from Merck KGaA (Darmstadt, Germany), Aminopropyl-terminated 
poly(dimethylsiloxane) was obtained from ABCR GmbH (Karlsruhe, Germany). All other 
chemicals and reagents were ordered from Sigma-Aldrich. Free amines in DMF were 
eliminated by aluminum oxide prior to usage. Solvent exchange was performed in dialysis 
tubes from Spectrum Laboratories (Spectrum Laboratories, cellulose ester, molecular weight 
cut-off (MWCO) 500–1000 Da or 3500–5000 Da, 3.2 cm/mL, wet in 0.05% sodium azide) 
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or in 24-well crystallization plates (HR3-158, Hampton Research) using water from a 
Milli-Q Direct 8 water purification system (Merck Millipore). 
7.2 Methods 
7.2.1 Peptide Synthesis, Purification and Characterization 
All peptides were synthesized by solid phase peptide synthesis using a Syro I peptide 
synthesizer (MultiSyn Tech GmbH, Witten, Germany). The syntheses of all peptides were 
performed at a 0.17 mmol scale on a Rink amide resin (0.71 mmol/g reactive group 
concentrations) using standard fluorenylmethoxycarbonyl (Fmoc) chemistry and HCTU 
coupling protocols. After each coupling cycle the unreacted peptide chains were acetylated 
using acetic acid anhydride (capping). At the end of the synthesis, the peptidyl resin was 
isolated and washed alternating with DMF, methanol, and dichloromethane. Acetylation of 
the N-terminus to obtain AcK6gA was performed using acetic acid anhydride prior to 
deprotection. Cleavage from the resin and removal of protective groups was performed for 
2 h in 10 mL containing 85% trifluoroacetic acid (TFA), 2.5% triisopropylsilane (TIS), 2.5% 
ethanedithiol (EDT), 5% thioanisole and 5% H2O for H3SSgT, a mixture of 95% TFA, 2.5% 
tetraethylsilane (TES), and 2.5% water for H3gT, K3gT, K10gA, and AcK6gA, and a mixture 
of 95% TFA, 2.5% EDT, and 2.5% water for CK3gT and K3gTC. The cleavage cocktail was 
filtered and the resin was washed additionally with 1 mL fresh cleavage cocktail. The filtrate 
was then precipitated in 40 mL cold diethyl ether (H3SSgT) or diisopropyl ether (all other 
peptides) and then pelleted by centrifugation. The precipitated crude peptides were washed 
with cold diethyl ether or diisopropyl ether and dried. The peptides were solubilized with 
ACN and aqueous TFA (0.05 %, v/v) and lyophilized. Purification was carried out by HPLC 
(Shimadzu Prominence 20A, Japan) on a C18 reverse phase (RP) column (Merck 
Chromolith, RP-18e, 100 mm × 10 mm and 100 mm × 4.6 mm) with mobile phases of water 
and acetonitrile containing 0.1% TFA while monitoring at 280 nm (gradient: 20–65% ACN). 
To obtain AcX3gT, AcCX3gT, and AcX3gTC, the peptides were solubilized in DMF 
(cysteine peptides were purged with O2) and acetylated using acetic acid anhydride. 
Products were purified using HPLC as described above. The molecular mass was determined 
by liquid chromatography electron spray ionization mass spectrometry (LC-ESI-MS) or 
matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF-
MS). LC-ESI-MS was performed using an LS instrument from Shimadzu, and an amaZon X 
MS from Bruker (Germany) with a water–acetonitrile gradient of 5% to 95% ACN over 10 
min (detection at 280 nm). The mass was obtained in positive mode and referenced to 
parabene. MALDI-ToF-MS samples were prepared by mixing 1 µL aliquots of a saturated α-
cyano-4-hydroxycinnamic acid stock solution in 50% ACN/0.1% TFA with 1 µL solubilized 
peptide on a BigAnchorChip MALDI plate. Spectra were acquired on a microflex instrument 
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from Bruker (Germany) using the reflector mode. The acceleration voltage was adjusted to 
19 kV and the reflector voltage to 20 kV. Data was collected for a mass range of 500–5000 Da 
using a detector gain voltage of 1400 V. Lyophilized peptides were stored in the freezer 
at -20°C. 
7.2.2 Film Preparation and Characterization 
Using a Hamilton syringe, aliquots of peptide solutions ranging from 50 to 120 mL in 
CHCl3:EtOH (90:10 v/v), were randomly dropped onto double-distilled H2O, held in a 
Langmuir-Blodgett (LB) trough (total area 420 cm2) from KSV, placed on an anti-vibration 
table in a dust-free room or, for LB film transfer, on a mini deposition trough (total area 
242 cm2) equipped with a dipper. After spreading, the solvent was allowed to evaporate for 
10 minutes, followed by compression of the film at 8 mm min-1. The surface pressure (p) of 
the monolayers was measured to ± 0.1 mN m-1 with a Wilhelmy plate (chromatography 
paper, ashless Whatman Chr 1) connected to an electro balance. Monolayers were 
compressed at 20 °C. LB-films were deposited on Si-wafers (previously cleaned in piranha 
solution (H2O2:H2SO4 = 3:7) for 10 min and rinsed in double-distilled H2O), freshly cleaved 
mica or template-stripped gold (TSG, prepared as described earlier196) by pulling the 
substrate out of the subphase through the interface at a constant rate of 0.5 mm min-1 while 
keeping p at 28 or 35 mN m-1. Immersion took place overnight (12 h) with freshly cleaved 
TSG in the corresponding solutions, followed by generous washing with ethanol. Samples 
were either dried in vacuum or were covered with buffer solution. For quartz crystal 
microbalance (QCM) measurements, frequency and dissipation shifts were monitored using 
the QSense D300 Quartz Crystal Microbalance (QSense, Gothenburg, Sweden). The QCM 
sensors consist of a disc-shaped, AT-cut piezoelectric quartz crystal coated with metallic 
electrodes on both sides. The QCM sensor crystal (1.4 cm diameter crystal, 1.2 cm diameter 
gold area, 0.2 cm2 active area, approximately 0.3 mm thickness, roughness of the electrode 
< 3 nm (rms)) operates at a resonance frequency of 4.95 MHz (50 kHz). The flow cell had 
an 80 µL working volume. Polarization-modulation infrared reflection-absorption spectra 
(PM-IRRAS) were recorded on a Bruker IFS equipped with a PMA 37 polarization-
modulation accessory. The maximum in polarization retardation was set at 2000 cm-1. 
Spectra were acquired with a 2 mm aperture and a resolution of 8 cm-1 using 1024 scans. The 
data was processed with OPUS software (Bruker Optics, Germany). 
7.2.3 Formation of Gold Nanoparticles 
Gold nanoparticles were prepared diluting 2.5 mL of a 10-2 M HAuCl4-solution with 
47.63 mL of water. After adjusting the pH to 8.0, 250 µL of a 0.1 M NaBH4 solution was 
added drop-wise, after which the color changed immediately to a dark reddish-brown.308 
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7.2.4 Formation of Composite Peptide–Gold Nanoparticle 
Superstructures 
The cysteine functionalized peptide AcX3gTC was dissolved in ethanol (0.5 mg/mL) 
containing one equivalent DTT to ensure the availability of the thiol functional groups on 
the peptides. After mild shaking for three days the gold nanoparticles were added to the 
peptide solution, in a ratio of 1:1, which corresponds to a 160-fold excess of peptide under 
the assumption of a hexagonal close packing of the peptide on the gold nanoparticle surface. 
After a reaction time of three days the mixture was purified from unreacted peptide by 
dialyzing against 50% ethanol (MWCO = 8–10 kDa) for 3–4 h with three times exchange of 
solvent. Self-assembly occurred by solvent exchange as described above. 
7.2.5 Characterization of Composite Peptide–Gold Nanoparticle 
Superstructures 
Atomic force microscopy (AFM) measurements were carried out using a 5100 Agilent 
system (formerly PicoLE Molecular Imaging) equipped with a multi-purpose scanner. 
Images were acquired using a silicon cantilever (type-NCHR PointProbe Plus, force constant 
42 N/m) for acoustic mode images. Data were prepared using the open-source software 
Gwyddion. SEM measurements were carried out using a Hitachi S-4800 operating at 5 keV. 
Aqueous peptide nanoparticle samples were transferred directly on the sample holder and 
were allowed to dry overnight. They were sputtered with platinum (5 nm). TEM 
micrographs were recorded on a FEI Morgani 268D operated at 80 keV. Samples were 
deposited on carbon-coated, parlodion- (2% in n-butyl acetate) covered copper grids and 
dried in air. When necessary, staining was performed with uranyl acetate (2% in H2O) for 
10 s. DLS measurements were performed with an ALV/CGS-8F platform-based goniometer 
system equipped with a HeNe laser at a wavelength of 633 nm (35 mW) and an ALV/-
5000/E correlator. Measurements were made at 20 °C and at a scattering angle between 30°–
150° in steps of 10°. Correlation functions were fitted by the 2nd cumulant function and 
extrapolated to zero wave vectors. Data analysis software ALV Stat 4.31 (ALV, Langen, 
Germany) was used.  
7.2.6 Peptide Nanoparticle Formation and Characterization 
To prepare peptide nanoparticles, peptides were dissolved in 50% ethanol to obtain 
1 mg/mL stock solutions and filtered through 0.2 µm hydrophilic syringe filters. Stock 
solutions were diluted to a concentration of 0.2 mg/mL using 50% ethanol and subsequently 
dialyzed for approximately 16 h against water in prewashed 500–1000 Da MWCO dialysis 
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tubes, renewing the exchange solvent twice. After removal of the samples from dialysis 
tubing, the size distribution was measured from diluted samples in water (1:10 v:v) by 
dynamic light scattering (DLS). DLS and zeta potential data were carried out using a Zeta 
Sizer Nano ZSP (Malvern Instruments Ltd., UK) at a fixed angle of θ = 173° with a laser 
beam wavelength of 633 nm at room temperature. Transmission electron microscope 
(TEM) imaging was performed on a Philips CM100 TEM operating at an acceleration 
voltage of 80 kV. Samples were incubated for 2 min on hydrophilized, carbon coated, 
parlodion-(2% in n-butyl acetate) copper grids, and when necessary were negatively stained 
with a 2% uranyl acetate solution (10 s incubation). SEM micrographs were taken on a 
Philips XL 30 ESEM operating at 5 kV. Samples were prepared on glass coverslips or mica 
and sputter-coated with silver or platinum. For energy dispersive X-ray spectroscopy (EDX) 
analysis an FEI Nova NanoSEM was used operating at 10 kV. AFM profiles were obtained 
from a NanoWizard III instrument from JPK Instruments AG using a PPP-NHCR cantilever 
(resonance frequency 204–497 kHz) and tapping mode in air. Confocal laser scanning 
micrographs (CLSM), fluorescence correlation spectroscopy (FCS), and fluorescence cross-
correlation spectroscopy (FCCS) data were recorded on a commercial Confocor2 (Carl 
Zeiss, Jena, Germany), equipped with a laser diode (405 nm), an Ar+ laser (514 nm), and 
two HeNe lasers for 543 and 633 nm, using a 40× C-Apochromat water immersion objective 
with a numeric aperture of 1.2. 
7.2.7 Payload Embedding and Characterization 
BODIPY 630/650 was diluted in dimethyl sulfoxide (DMSO) to 1.5 mM, aliquoted and 
stored in the freezer at –20°C. 1 µL of 1.5 mM of BODIPY was mixed with 100 µL peptide 
stock solutions (1 mg/mL), diluted to 500 µL with 50% ethanol and then dialyzed as 
described above. AON-loaded peptide nanoparticles were prepared by addition of 4 µL of 
100 µM AON solution to 100 µL peptide stock solutions (1 mg/mL) and diluted to 500 µL 
with 35% ethanol. For loading particles with plasmid DNA the plasmid DNA was incubated 
for 15 min with peptides at different N/P-ratios in 30% ethanol, followed by dialysis to water, 
renewing exchange solvent twice. Coloading was performed by mixing 4 µL of 100 µM AON 
with 1 µL of 1.5 mM BODIPY and 100 µL of 1 mg/mL peptide, further diluted to 500 µL 
with 35% ethanol and dialyzed. DoxHCl-peptide nanoparticles were prepared by adding 
40 µL of a 10 mM DoxHCl solution in DMSO to 400 µL peptide stock solution, then diluted 
to 2 mL with 50% ethanol, mixed and dialyzed as described above. DoxHCl-peptide 
nanoparticles were separated from nonembedded payload via three centrifugation–
decantation cycles (29700 RCF at 5°C). DoxHCl-loading was quantified by fluorescence 
(PerkinElmer LS55 Luminescence Spectrometer, excitation wavelength: 490 nm, emission 
wavelength: 555 nm) using a standard dilution curve of DoxHCl. Loading of peptide 
nanoparticles with BODIPY and AON was measured by FCS. For BODIPY a HFT 633 / LP 
650 filter set was used with a pinhole size of 90 µm and a 633 nm laser with a laser power of 
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5%, while AON was measured using a HFT 543 / LP 560 filter set with a pinhole size of 78 
µm and a 543 nm laser at 5% laser power. Loading was confirmed by CLSM for all three 
payloads: BODIPY, AON, and DoxHCl. For BODIPY a 633 nm laser at 10% transmission 
was used with NFT 545 and LP 650 filters with a pinhole of 92 µm, AON fluorescence was 
acquired using a 543 nm laser at 20% transmission and HFT 488/543 and LP 560 filters with 
a pinhole of 78 µm. DoxHCl was detected using a 488 nm laser at 9.9% transmission with 
HFT 488, NFT 545, and LP 560 filters and a pinhole of 78 µm. pDNA-loaded particles were 
prepared by addition 6 µL of a stock solution of 960 µg/mL pDNA to appropriate amounts of 
ethanolic (30 %) peptide solutions to obtain the desired N/P-ratios. Nanoparticles were 
formed by dialysis as described above.  
7.2.8 Release Experiments From BODIPY/AON-Loaded 
Nanoparticles 
Release experiments were performed by mixing 45 µL of BODIPY- or AON-loaded peptide 
nanoparticles (0.2 mg/mL) with 5 µL of 100 mM dithiothreitol (DTT) dissolved in 100 mM 
HEPES buffer at pH 7.2 to obtain a 10 mM DTT solution. As control experiments, loaded 
peptide nanoparticles were diluted with 100 mM HEPES pH 7.2 to obtain 10 mM buffer 
concentration. Samples were stirred at room temperature and at indicated time points (2–
120 min) 5 µL aliquots were withdrawn and measured subsequently 15 x 5 s by FCS (see 
payload embedding section for instrument settings). FCS data was fitted with a two-
component model, where component 1 was fixed to a free payload diffusion (about 61 µs for 
BODIPY and about 102 µs for AON) (without triplet state), the structural parameter was 
fixed to 5. All release experiments were performed in triplicate with error bars representing 
the standard error. TEM micrographs after DTT treatment were obtained using the 
conditions described above. 
7.2.9 Characterization of BODIPY/AON-Coloaded Nanoparticles 
Peptide nanoparticles were prepared as mentioned above. 5 µL aliquots of nanoparticles were 
placed on a glass slide and micrographs were acquired right above the surface. CLSM 
micrographs were obtained using a HFT UV/488/543/633, NFT 545, LP 650, and BP 530–
600 filter set with 9.9% laser power and a pinhole of 82 µm for the 633 nm laser and 16% laser 
power and a pinhole of 76 µm for the 543 nm laser. Images were processed and brightness 
profiles were obtained from the LSM image browser (Zeiss). FCCS data was recorded using 
HFT 514, LP 650, and BP 530–600 filters; a 514 nm laser at 20% transmission with a pinhole 
of 70 µm and a 633 nm laser at 5% transmission with a 70 µm pinhole. All data was fitted 
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using a one-component model without triplet state and a structural parameter of 5 using 
ConfoCor3 software to obtain autocorrelation and the cross-correlation functions: 
G τ fit = 1 + !! !!! !!D !!!!! !!D  (9) 
τD is the diffusion time, N the number of particles, and R the structural parameter (was fixed 
to 5). Relative cross-correlation amplitudes (RCA) were calculated using the cross-
correlation amplitude Gx(0) and the autocorrelation amplitudes of the AON and BODIPY 
channels GAON,BODIPY(0), respectively: 𝑅𝐶𝐴 = !!(!)!! !!"#,!"#$%& ! !! (10) 
The coloading degree (CLD) was calculated by normalizing the data where the minimal 
cross-correlation of a mixture of both payloads in solution was set to 0% and the maximal 
cross-correlation from a double-labeled DNA standard (IBA standard) was set to 100%. 
7.2.10 Electrophoretic Mobility Shift Assay 
Electrophoretic Mobility Shift Assays (EMSA) were performed on 1.2% agarose gels using 
TEA buffer. A constant voltage of 100 V was applied and gels were run for 40–50 min. 
Sample volumes were kept at 10 µl. 2 µl loading dye (6× Mass Ruler DNA loading dye from 
Thermo Scientific) was added prior to electrophoresis. Agarose gels were stained with 
GelRed dye (Biotinum, USA). On each gel the first lane represents the pDNA control. For 
release experiments samples were incubated for indicated time periods in 200 mM DTT 
solutions in HEPES pH 7.2 at room temperature prior to analysis.  
7.2.11 Cell Culture 
HeLa and U87 cells were grown in Dulbecco’s modified eagle medium (DMEM) with 10% 
fetal bovine serum (FBS), 100 units/mL penicillin and 100 µg/mL streptomycin and 
maintained at 37 °C in 5% CO2. 
7.2.12 Cell Viability Assay (MTS) 
Cytotoxicity analysis was performed using the Promega CellTiter 96 AQueous Non-
Radioactive Cell Proliferation (MTS) assay to determine the number of viable cells in 
Severin J. Sigg 
104 
culture. Triplicate or quintuplicate wells containing 2000–5000 HeLa or U87 cells were 
seeded in a 96-well plate 24 h prior to the experiment in order to achieve confluency at the 
time of analysis. 10 µL aliquots of peptide nanoparticle solution were added to the cells to 
give final concentrations between 50–300 µg/mL or 25–1000 µg/mL and incubated for 24 or 
48 h at 37°C with 5% CO2. MTS solution (20 µL/well) was added to the cells and then 
incubated for 2h. Cell viability in each well was calculated by measuring the absorbance of 
the cell solution (cells and media containing the nanoparticles) mixed with MTS solution at 
490 nm using a SpectraMax M5e (Molecular Device) spectrometer with a plate reader, and 
data was normalized against cells incubated with water or HEPES buffer (100% viability) and 
background subtracted with the absorbance from the MTS alone. To obtain IC50 values the 
experimental viability was fitted using exponential curves. 
7.2.13 Cell Uptake of BODIPY- and/or AON-Loaded 
Nanoparticles 
HeLa (2×104 or 5×104 cells per well) were seeded into an 8-well chamber 24 h prior to the 
experiment. After 24 hours, the cell culture media was replaced with Opti-MEM (130 µL) 
followed by addition of 20 µL 0.2 mg/mL peptide nanoparticles. After 4 h incubation, the cell 
culture medium was replaced with serum-containing media (300 µL). The cells were then 
incubated for another 20 h. For cell uptake with serum the medium supplemented with 10% 
FBS was renewed prior to sample application. Prior to live cell imaging, the media was 
replaced by phosphate buffered saline (PBS) and the cell nuclei were stained for 10 min with 
1.6 µL of a 50 µg/mL Hoechst 33342 solution in PBS. Cell imaging was performed by 
CLSM. The samples were excited at 405 nm (Hoechst 33342), 543 nm (for AON), and 633 
nm (for BODIPY) while collecting the emission after a BP 420–480 filter (Hoechst 33342), 
a BP 530–600 filter (AON), and a LP 650 filter (BODIPY), respectively. Images were taken 
with the same acquisition settings for comparison purposes. 
7.2.14 Imaging of GFP-Transfected Cells 
U87 cells (5×104 cells per well) were seeded into an 8-well chamber 24 h prior to the 
experiment. The cell culture medium was replaced by Opti-MEM (130 µL) followed by 
addition of samples to obtain 1 µg pDNA/well. After 4 h, the cell culture media was replaced 
by serum-containing media (300 µL). Prior to imaging, the media was replaced by PBS. 
Imaging was performed by CLSM using 488 nm laser at 5.0% transmission collecting the 
emission after an LP 505 filter. 
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7.2.15 Flow Cytometry Analysis  
HeLa or U87 cells (7×104 or 5×104 cells/well) were plated into 24-well tissue culture plates 
24 h prior to the experiment. The cell culture media was replaced with serum-free media 
(460 µL) and 40 µl 0.2 mg/mL peptide nanoparticles were added. After 4 h incubation, the 
serum-free medium was carefully removed and replaced with 1 ml of medium containing 
10% FBS. The cells were then incubated another 20 or 44 h. Cells were trypsinized with 200 
µl of trypsin for 10 min at 37 °C and 5% CO2. Following trypsinization, 800 µl PBS were 
added to the cells, gently mixed by pipetting and transferred into 1.5 mL microcentrifuge 
tubes. Cells were then pelleted by centrifugation at 200 RCF for 5 min. Subsequently, the 
media was aspirated and the pellet was resuspended in 250 µl PBS (for cell uptake studies) or 
400 µL (transfection and toxicity studies) and put on ice. 6 µL aliquots of 50 µg/mL stock 
solution of Hoechst 33342 were added to each sample. For propidium iodide (PI)–Hoechst 
assays 1 µL aliquots of 1 mg/mL stock solutions of PI and 0.5 µL aliquots of 5 mg/mL stock 
solutions of Hoechst 33342 were added to each sample. Immediately prior to fluorescence 
assisted cell sorting (FACS) analysis, the cells were vortexed gently. FACS measurements of 
AON-loaded nanoparticles were performed by measuring at least 3×104 cells with a BD LSR 
Fortessa, the cells were excited with lasers at 405 and 561 nm, the emitted light passed 
through band-pass 450/50 and 586/15 filters, respectively. The data were processed with 
FlowJo Vx (Tree Star, USA) and a fluorescence histogram of viable cells only was plotted or 
the mean fluorescence intensity was extracted. Flow cytometry analysis of GFP-transfected 
cells were performed by measuring at least 2×104 cells. The cells were excited using 405 and 
488 nm lasers, and 450/50 and 529/24 band-pass filters. For Hoechst 33342–propidium 
iodine staining 405 and 488 nm lasers and 450/50 and 585/40 band-pass filters were applied. 
Transfection efficacies and relative populations were obtained by gating forward- versus side-
scattering plots and GFP-histograms relative to nontreated control cells. Toxicities were 
calculated by gating the cell counts using a propidium iodide (PI) versus Hoechst 33342-plot 
according to nontreated control cells. 
7.2.16 Heparin-PDMS Synthesis 
Heparin-PDMS block copolymer was synthesized as reported previously.294 Briefly, heparin 
sodium salt was converted to tetrabutylammonium salt using a Dowex Marathon MSC 
column (Sigma-Aldrich, 428787) neutralizing to pH 7 with tetrabutylammonium hydroxide 
solution (Sigma-Aldrich, 86863). The product was purified via dialysis against water for at 
least 48 h (Spectrum Laboratories Inc., CA, USA, MWCO 3.5–5 kDa) and dried.  Heparin 
tetrabutylammonium salt was reacted with PDMS(NH2)2 for 7 days, then precipitated in 
diethyl ether, washed, purified and dried. 
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7.2.17 Gadolinium-Complex and Nanoparticle Formation and 
Characterization 
HepPDMS was dissolved in 50% ethanol and filtered (0.45 µm) to obtain a 17 mg/mL clear 
solution. After dilution to 4.25 mg/mL and pH adjustment to pH 7 using diluted NaOH, the 
solution was dialyzed against water for 16 h, renewing exchange solvent twice, using 
prewashed 500–1000 Da MWCO dialysis tubes. HepPDMS-Gd nanoparticles were formed 
by adding gadolinium chloride hexahydrate stock solution (27 mM) dropwise under stirring 
to above described hepPDMS stock solution (17 mg/mL). The pH was readjusted to 7 when 
necessary, diluted to 4.25 mg/mL HepPDMS and to a final gadolinium concentration of 2.4 
mM, then dialyzed to water as described above. For production of coassemblies the peptides 
were first dissolved in 50% ethanol to obtain 1 mg/mL stock solutions and then filtered 
through 0.2 µm hydrophilic syringe filters.  HepPDMS-Gd stock solutions (8.5 mg/mL) 
were mixed 1:1 with peptide stock solution and subsequently dialyzed as described above. 
7.2.18 Cell Uptake of Gadolinium Constructs 
Hela cells (5×104 cells per well) were seeded in triplicates into a 24-well chamber 24 h prior 
to the experiment. The cell culture media was replaced with Opti-MEM (150 µL) followed 
by addition of 20 µL peptide HepPDMS-Gd nanoparticles. After 4 h incubation, the cell 
culture medium was removed and replaced with serum-containing medium (500 µL). The 
cells were then incubated for another 20 h. Cells were washed with opti-MEM, trypsinized, 
transferred to Falcon tubes and digested in 65% HNO3 over night. Subsequently, the 
gadolinium-content was determined using inductively coupled plasma optical emission 
spectroscopy (ICP-OES). 
7.2.19 Inductively Coupled Plasma-Optical Emission Spectroscopy 
All gadolinium contents were determined by inductively coupled plasma-optical emission 
spectroscopy (ICP-OES). Quantification of gadolinium was carried out on a Ciros Vision 
ICP-OES from Spektro (Kleve, Germany) in axial mode. Gadolinium stock solutions of 
known metal content were measured prior to sample measurements to plot calibration 
curves. All samples were digested by 65% HNO3 over night and diluted to 2% HNO3 prior to 
analysis. 
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7.2.20 Anticoagulation Activity 
The anticoagulation activity was determined by a Biophen Heparin (LRT) kit determining 
the absorption of cleaved pNA, indirectly based on the inhibition of factor Xa in the 
coagulation cascade. The absorbance was measured at 405 nm using a STA-R analyzer from 
Stago. 
7.2.21 Farndale Microassay 
Accessible heparin was determined by Farndale microassay as described previously.294,309 
Briefly, 250 µl 1,9-dimethylmethylene blue (DMMB) stock solution was mixed with 50 µl 
heparin standards (2.5–20 µg/mL). Samples were diluted to the range of the calibration 
curve using PBS. Absorption was measured at 525 nm and the heparin levels of samples were 
calculated using a standard dilution curve. 
7.2.22 Xylenol Orange Assay 
Free gadolinium levels were analyzed by xylenol orange assay according to a published 
procedure.310 Briefly, xylenol orange tetrasodium salt was diluted in 10 mM HEPES buffer 
pH 6 to obtain a 12 µg/mL stock solution. Samples were diluted to the linear range and 10 µL 
aliquots were mixed with 100 µL xylenol orange stock solution. For stability tests samples 
where maintained in opti-MEM with FBS, after 7 days 10 µL sample was added to 100 µL 
stock solution in triplicates and absorption was measured at 433 and 473 nm. Gadolinium-
ion concentration was calculated using a calibration curve of the ratio of absorption at 573 
and 433 nm plotted against gadolinium-concentration. 
7.2.23 Electron Paramagnetic Resonance Spectroscopy 
Electron paramagnetic resonance (EPR) spectra were recorded with a CW Bruker 
ElexSys500 X-band CW spectrometer, to which the superQ wave-guide resonance cavity 
(ER4122 SHQE-W1) was attached. Microwave power was adjusted at levels below the 
saturation condition with values 2.0–6.0 mW. The modulation frequency was 100 kHz and 
the modulation amplitude was 0.9 mT; other spectral parameters were adjusted for each 
spectrum individually. 80 spectra were acquired to optimize the signal-to-noise ratio, and 3rd-
order polynomial averaging was used for subsequent noise reduction. Gd samples were 
measured at room temperature. Lorentzian line shapes were considered with the line-width 
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adjusted for each spectrum. The peak-to-peak line width was measured from the spectrum 
using the WINEPR software. The pH of the samples was adjusted to 7 with NaOH. 
7.2.24 Magnetic Resonance Imaging 
Samples were measured in 1.5 mL centrifuge vials in denoted concentrations. For imaging a 
3T clinical human MRI scanner was used from Siemens was used. The T1 relaxation times 
were measured using an inversion recovery prepared spin echo sequence with the following 
acquisition parameters: voxel size 1.2×1.2×5 mm3, TR/TE 6000/12 ms. The scan was 
repeated at various inversion times (TI): 50 ms, 100 ms, 200 ms, 500 ms, 750 ms, 1000 ms, 
and 2000 ms. The T2 relaxation times of the samples were measured using a multi-echo spin 
echo sequence with the following acquisition parameters: voxel size 1.2×1.2×5 mm3, TR 
3000 ms. 32 echoes were acquired with a 13.2 ms echo spacing (first echo: 13.2 ms, last echo: 
422.4 ms). 
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